Funders › NY › The Leona M and Harry B Helmsley Charitable Trust › 2024
Grants paid by The Leona M and Harry B Helmsley Charitable Trust, tax year 2024
EIN 13-7184401 · New York, NY · Form 990-PF, Part XV · NTEE T20
In tax year 2024, The Leona M and Harry B Helmsley Charitable Trust (EIN 13-7184401) reported 594 grants paid totaling $445,672,622. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2024 · page 1 of 2
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Ben-Gurion University of the Negev Beer Sheva | D | $10,542,857 | approved, future | CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING | 202530289349100408 |
| 2024 | Mass General Brigham for the Brigham and Women's Hospital Boston, MA | U | $9,013,397 | paid | PEN-PLUS EXPANSION | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $6,966,024 | approved, future | AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH | 202530289349100408 |
| 2024 | Tel-Aviv University Tel Aviv | D | $6,828,500 | approved, future | HELMSLEY MEDICAL SIMULATION CENTER | 202530289349100408 |
| 2024 | Commonwealth Healthcare Corporation Saipan | U | $6,440,191 | paid | CNMI CHCC MRI/MEDICAL EQUIPMENT UPGRADE PROJECT | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $5,928,622 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $5,928,622 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Ben-Gurion University of the Negev Beer Sheva | D | $5,785,714 | approved, future | CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $5,772,918 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $5,772,917 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Tzafon Medical Center Tiberias | U | $5,431,730 | paid | THE HELMSLEY REHABILITATION CENTER OF THE NORTH | 202530289349100408 |
| 2024 | St Luke Health Care Foundation West Chicago, IL | C | $5,201,874 | approved, future | HOPE CENTER FOR WOMEN AND CHILDREN | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $5,200,000 | paid | LINEAR ACCELERATORS FOR THE RADIOTHERAPY INSTITUTE | 202530289349100408 |
| 2024 | Stichting the Ocean Cleanup Rotterdam | U | $5,000,000 | paid | DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS | 202530289349100408 |
| 2024 | Billings Clinic Foundation Billings, MT | B | $5,000,000 | approved, future | BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $5,000,000 | approved, future | DEVELOPMENT OF THE HELMSLEY SURGICAL WING | 202530289349100408 |
| 2024 | Stichting the Ocean Cleanup Rotterdam | U | $5,000,000 | approved, future | DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $5,000,000 | paid | DEVELOPMENT OF THE HELMSLEY SURGICAL WING | 202530289349100408 |
| 2024 | Stichting the Ocean Cleanup Rotterdam | U | $5,000,000 | approved, future | DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS | 202530289349100408 |
| 2024 | St Rose Dominican Health Foundation Henderson, NV | U | $4,925,243 | paid | DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $4,903,870 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $4,903,869 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Fairview Health Services Minneapolis, MN | B | $4,889,200 | paid | IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $4,885,390 | paid | MINNESOTA FIRST RESPONDER AED PROJECT | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $4,816,553 | approved, future | AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH | 202530289349100408 |
| 2024 | St Luke Health Care Foundation West Chicago, IL | C | $4,790,316 | approved, future | HOPE CENTER FOR WOMEN AND CHILDREN | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $4,557,698 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $4,557,698 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $4,470,844 | approved, future | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $4,470,843 | approved, future | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | The Sheba Fund for Health Services and Research (ra) Ramat Gan | U | $4,395,700 | paid | THE HELMSLEY CENTER FOR INNOVATIVE SURGICAL TRAINING | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $4,336,124 | approved, future | VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES | 202530289349100408 |
| 2024 | Diabetes Nsw Sydney | U | $4,299,165 | approved, future | IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $4,194,494 | paid | AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH | 202530289349100408 |
| 2024 | The End Fund Inc New York, NY | B | $4,130,500 | paid | REACHING THE LAST MILE FUND EXPANSION | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,982,146 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,982,146 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $3,975,887 | approved, future | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | New York University School of Medicine New York, NY | C | $3,692,303 | paid | TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH | 202530289349100408 |
| 2024 | Central Montana Medical Facilities Inc Lewistown, MT | B | $3,690,035 | paid | CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,640,094 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,640,094 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | World Health Organization Geneva | U | $3,521,461 | approved, future | STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,500,510 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,500,510 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | State of Nevada Department of Division of State Parks Carson City, NV | U | $3,500,000 | approved, future | VALLEY OF FIRE VISITOR CENTER | 202530289349100408 |
| 2024 | State of Nevada Department of Division of State Parks Carson City, NV | U | $3,500,000 | paid | ICE AGE FOSSIL STATE PARK TRAILS AND OUTDOOR AMENITIES | 202530289349100408 |
| 2024 | State of Nevada Department of Division of State Parks Carson City, NV | U | $3,500,000 | paid | VALLEY OF FIRE VISITOR CENTER | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $3,500,000 | approved, future | DEVELOPMENT OF THE HELMSLEY SURGICAL WING | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $3,480,533 | paid | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | World Health Organization Geneva | U | $3,477,889 | approved, future | STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,470,012 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $3,470,011 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $3,358,835 | approved, future | A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER | 202530289349100408 |
| 2024 | Bar Ilan University Ramat Gan | U | $3,348,125 | approved, future | THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY | 202530289349100408 |
| 2024 | Bar Ilan University Ramat Gan | U | $3,216,875 | paid | THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY | 202530289349100408 |
| 2024 | Fairview Health Services Minneapolis, MN | B | $3,176,500 | approved, future | IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE | 202530289349100408 |
| 2024 | Hillel Yaffe Medical Center Hadera | U | $3,158,400 | approved, future | EYE INSTITUTE AND AMBULATORY SURGERY CENTER | 202530289349100408 |
| 2024 | Corewell Health Grand Rapids, MI | U | $3,104,271 | approved, future | EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS | 202530289349100408 |
| 2024 | Clinton Health Access Initiative Inc Boston, MA | B | $3,057,795 | paid | IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $3,039,905 | approved, future | VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES | 202530289349100408 |
| 2024 | St Luke Health Care Foundation West Chicago, IL | C | $3,026,254 | paid | HOPE CENTER FOR WOMEN AND CHILDREN | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $3,000,000 | approved, future | EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $3,000,000 | paid | EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $3,000,000 | approved, future | EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE | 202530289349100408 |
| 2024 | Anthos Home Inc Brooklyn, NY | C | $3,000,000 | approved, future | LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS | 202530289349100408 |
| 2024 | Tel-Aviv University Tel Aviv | D | $3,000,000 | paid | HELMSLEY MEDICAL SIMULATION CENTER | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $2,978,657 | approved, future | VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,929,862 | paid | CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | World Health Organization Geneva | U | $2,862,039 | paid | STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS | 202530289349100408 |
| 2024 | Living Water International Stafford, TX | B | $2,838,602 | paid | SCALING INTEGRATED WASH SERVICES | 202530289349100408 |
| 2024 | Clinton Health Access Initiative Inc Boston, MA | B | $2,811,261 | approved, future | IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION | 202530289349100408 |
| 2024 | The Association for the Resident and Community in Ramat Hanegev Ramat Hanegev | U | $2,775,467 | approved, future | RAMAT HANEGEV SENIOR CITIZEN CENTER | 202530289349100408 |
| 2024 | New York University School of Medicine New York, NY | C | $2,756,847 | approved, future | TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH | 202530289349100408 |
| 2024 | World Health Organization Geneva | U | $2,738,915 | approved, future | STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT | 202530289349100408 |
| 2024 | Weizmann Institute of Science Rehovot | D | $2,700,000 | approved, future | QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS | 202530289349100408 |
| 2024 | Reachanother Foundation Bend, OR | U | $2,667,559 | paid | EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA | 202530289349100408 |
| 2024 | The Academic College at Tel-Hai Upper Galilee | U | $2,664,333 | approved, future | THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH | 202530289349100408 |
| 2024 | World Health Organization Geneva | U | $2,658,639 | approved, future | STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS | 202530289349100408 |
| 2024 | Bridges to Prosperity Inc Denver, CO | D | $2,648,126 | paid | TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA | 202530289349100408 |
| 2024 | The Academic College at Tel-Hai Upper Galilee | U | $2,600,000 | approved, future | THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING. | 202530289349100408 |
| 2024 | Living Water International Stafford, VA | C | $2,574,349 | approved, future | SCALING INTEGRATED WASH SERVICES | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $2,567,417 | approved, future | EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $2,567,417 | paid | DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $2,541,165 | approved, future | A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $2,521,277 | approved, future | MISSION: LIFELINE STROKE IOWA | 202530289349100408 |
| 2024 | Civica Foundation Lehi, UT | B | $2,500,000 | paid | AFFORDABLE INSULIN | 202530289349100408 |
| 2024 | Civica Foundation Lehi, UT | B | $2,500,000 | paid | AFFORDABLE INSULIN | 202530289349100408 |
| 2024 | Sheridan County Memorial Hospital Foundation Sheridan, WY | B | $2,500,000 | paid | SHERIDAN MEMORIAL HOSPITAL EMPATH AND CRISIS STABILIZATION UNIT | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,466,114 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,466,113 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202530289349100408 |
| 2024 | International Water Management Institute Battaramulla | D | $2,449,440 | approved, future | DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA | 202530289349100408 |
| 2024 | Living Water International Stafford, VA | C | $2,432,337 | approved, future | SCALING INTEGRATED WASH SERVICES | 202530289349100408 |
| 2024 | The Sderot Development Foundation Sderot | U | $2,421,222 | paid | ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT | 202530289349100408 |
| 2024 | Ezrath Nashim Sarah Herzog Memorial Hospital Jerusalem | U | $2,384,174 | paid | CONSTRUCTION OF A NEW MENTAL HEALTH FACILITY AT HERZOG MEDICAL CENTER | 202530289349100408 |
| 2024 | Bridges to Prosperity Inc Denver, CO | D | $2,359,636 | approved, future | TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,348,061 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Ann & Robert H Lurie Childrens Hospital of Chicago Chicago, IL | B | $2,325,006 | approved, future | IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D | 202530289349100408 |
| 2024 | Bridges to Prosperity Inc Denver, CO | D | $2,306,101 | approved, future | TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA | 202530289349100408 |
| 2024 | The Scripps Research Institute La Jolla, CA | B | $2,265,175 | paid | GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD | 202530289349100408 |
| 2024 | Nuru International Washington, DC | B | $2,250,000 | paid | EXPANSION OF AGRIBUSINESS COOPERATIVES | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,240,499 | paid | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202530289349100408 |
| 2024 | Renown Health Foundation Reno, NV | B | $2,211,453 | paid | RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $2,203,040 | approved, future | VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES | 202530289349100408 |
| 2024 | Galilee Medical Center Nahariya | U | $2,200,000 | approved, future | RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER | 202530289349100408 |
| 2024 | Galilee Medical Center Nahariya | U | $2,200,000 | paid | RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER | 202530289349100408 |
| 2024 | Sightsavers Inc Boston, MA | B | $2,193,748 | paid | TRACHOMA ELIMINATION IN ZAMBIA | 202530289349100408 |
| 2024 | Chi Health Foundation Omaha, NE | U | $2,165,669 | paid | ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $2,159,000 | paid | A PHOTON COUNTING DETECTOR-CT DEVICE FOR SOROKA MEDICAL CENTER | 202530289349100408 |
| 2024 | The Laniado Kiriat Sanz Hospital Nataniya | U | $2,150,000 | paid | NEW MATERNITY FLOOR C | 202530289349100408 |
| 2024 | Ziv Medical Center Zefat Zefat | U | $2,120,034 | paid | PRESSURE CHAMBER FOR HYPERBARIC THERAPY, ZIV MEDICAL CENTER, SAFED. | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,114,441 | paid | CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | High Quality Medical Education Afton, MN | B | $2,112,639 | approved, future | POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $2,105,298 | paid | MISSION: LIFELINE STROKE IOWA | 202530289349100408 |
| 2024 | Corewell Health Grand Rapids, MI | U | $2,081,202 | approved, future | EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS | 202530289349100408 |
| 2024 | The Trevor Project Inc West Hollywood, CA | B | $2,081,072 | approved, future | LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT | 202530289349100408 |
| 2024 | The Academic College at Tel-Hai Upper Galilee | U | $2,078,769 | approved, future | THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH | 202530289349100408 |
| 2024 | Monument Health Inc Rapid City, SD | C | $2,066,019 | paid | NICU EQUIPMENT | 202530289349100408 |
| 2024 | A Glimmer of Hope Foundation Austin, TX | C | $2,053,426 | paid | EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $2,029,929 | approved, future | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202530289349100408 |
| 2024 | Minnesota Academy of Family Physicians Foundation Minneapolis, MN | C | $2,016,319 | approved, future | POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS | 202530289349100408 |
| 2024 | Holy Rosary Healthcare Foundation Miles City, MT | B | $2,000,000 | paid | HOLY ROSARY HEALTHCARE COMPREHENSIVE CANCER CENTER | 202530289349100408 |
| 2024 | Hadassah Medical Organization Jerusalem | U | $2,000,000 | paid | EQUIPPING HADASSAH HOSPITAL'S OPERATING ROOMS | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $2,000,000 | paid | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $2,000,000 | paid | EMERGENCY SUPPORT FOR SOROKA MEDICAL CENTER: MEDICAL EQUIPMENT | 202530289349100408 |
| 2024 | Billings Clinic Foundation Billings, MT | B | $2,000,000 | approved, future | BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT | 202530289349100408 |
| 2024 | International Water Management Institute Battaramulla | D | $1,999,629 | paid | DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA | 202530289349100408 |
| 2024 | Schwartzreisman Science Education Center Rehovot (ra) Rehovot | U | $1,982,305 | paid | THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT | 202530289349100408 |
| 2024 | Yitzhak Shamir Medical Center Tzrifin | U | $1,978,286 | approved, future | EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $1,975,490 | paid | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $1,974,021 | approved, future | DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT | 202530289349100408 |
| 2024 | Fairview Health Services Minneapolis, MN | B | $1,960,000 | paid | IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,956,717 | paid | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,945,286 | approved, future | PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,927,629 | approved, future | CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $1,920,614 | paid | DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $1,917,417 | approved, future | EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY | 202530289349100408 |
| 2024 | Bridges to Prosperity Inc Denver, CO | D | $1,915,763 | paid | TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA | 202530289349100408 |
| 2024 | Ncd Alliance Geneva | U | $1,911,525 | paid | 2023-2025 PARTNERSHIP | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $1,888,240 | paid | VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES | 202530289349100408 |
| 2024 | American Samoa Medical Center Authority Pago Pago, AS | U | $1,878,805 | paid | MRI AT LBJ TROPICAL MEDICAL CENTER | 202530289349100408 |
| 2024 | Banner Health Foundation Phoenix, AZ | B | $1,869,864 | paid | BANNER HEALTH WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | National Park Foundation Washington, DC | B | $1,850,000 | paid | BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,849,482 | paid | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,845,255 | paid | HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE | 202530289349100408 |
| 2024 | The Scripps Research Institute La Jolla, CA | B | $1,836,022 | approved, future | GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD | 202530289349100408 |
| 2024 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,808,630 | approved, future | EXPANDING COMMUNITY RECOVERY AND RESILIENCE | 202530289349100408 |
| 2024 | Minnesota Academy of Family Physicians Foundation Minneapolis, MN | C | $1,801,545 | approved, future | POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS | 202530289349100408 |
| 2024 | Oregon Health & Science University Portland, OR | U | $1,795,816 | approved, future | AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT | 202530289349100408 |
| 2024 | Convergent Impact Inc Boulder, CO | B | $1,795,546 | paid | COLLABORATIVE ON HOUSING FOR HEALTH | 202530289349100408 |
| 2024 | Mass General Brigham for the Brigham and Women's Hospital Boston, MA | U | $1,785,375 | paid | BUILDING A GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND OTHER SEVERE CHRONIC NONCOMMUNICABLE DISEASES | 202530289349100408 |
| 2024 | Oregon Health & Science University Portland, OR | U | $1,783,316 | approved, future | AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,761,496 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,761,496 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $1,750,000 | paid | THE QUANTUM MATERIALS DEVICES FABRICATION LAB | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $1,740,267 | paid | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | Blue Circle Health Inc Wilmington, DE | U | $1,740,266 | paid | DEVELOPMENT OF BLUE CIRCLE HEALTH | 202530289349100408 |
| 2024 | The Regents of the University of California at Irvine Irvine, CA | C | $1,729,516 | approved, future | DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Mass General Brigham for the Massachusetts General Hospital Boston, MA | U | $1,728,414 | paid | MICROBES, MOLECULES, AND CHEMISTRY: DYSBIOSIS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Mass General Brigham for the Massachusetts General Hospital Boston, MA | U | $1,722,621 | approved, future | MICROBES, MOLECULES, AND CHEMISTRY: DYSBIOSIS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | High Quality Medical Education Afton, MN | B | $1,705,225 | approved, future | POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS | 202530289349100408 |
| 2024 | Diabetes Nsw Sydney | U | $1,700,835 | paid | IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,676,154 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,676,153 | approved, future | THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A) | 202530289349100408 |
| 2024 | Water4 Inc Oklahoma City, OK | C | $1,673,164 | paid | SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER | 202530289349100408 |
| 2024 | Helen Keller International New York, NY | C | $1,652,490 | paid | A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT | 202530289349100408 |
| 2024 | Scripps Health La Jolla, CA | B | $1,636,800 | approved, future | CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS | 202530289349100408 |
| 2024 | Fund for Public Housing Inc New York, NY | B | $1,630,000 | paid | DEVELOPING AND ACTIVATING GREENSPACE USING THE CONNECTED COMMUNITIES' PARTICIPATORY PROCESS AT FOUR NYCHA DEVELOPMENTS | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $1,623,623 | paid | DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT | 202530289349100408 |
| 2024 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,617,611 | paid | EXPANDING COMMUNITY RECOVERY AND RESILIENCE | 202530289349100408 |
| 2024 | Amc Medical Research Bv Amsterdam | U | $1,607,013 | paid | A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN | 202530289349100408 |
| 2024 | Project Concern Zambia Limited Lusaka | U | $1,590,680 | approved, future | EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS | 202530289349100408 |
| 2024 | Ncd Alliance Geneva | U | $1,582,350 | approved, future | 2023-2025 PARTNERSHIP | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $1,574,759 | approved, future | EDENT1FI | 202530289349100408 |
| 2024 | Safe Water Network New York, NY | B | $1,552,050 | paid | SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $1,551,603 | approved, future | EDENT1FI | 202530289349100408 |
| 2024 | International Water Management Institute Battaramulla | D | $1,550,680 | approved, future | DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA | 202530289349100408 |
| 2024 | Ann & Robert H Lurie Childrens Hospital of Chicago Chicago, IL | B | $1,542,882 | approved, future | IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D | 202530289349100408 |
| 2024 | Share Trust Inc Dover, MA | C | $1,540,658 | approved, future | BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION | 202530289349100408 |
| 2024 | Share Trust Inc Dover, MA | C | $1,540,658 | approved, future | BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION | 202530289349100408 |
| 2024 | The Trevor Project Inc West Hollywood, CA | B | $1,536,740 | approved, future | LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT | 202530289349100408 |
| 2024 | Amc Medical Research Bv Amsterdam | U | $1,532,103 | approved, future | A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN | 202530289349100408 |
| 2024 | Tel-Aviv University Tel Aviv | D | $1,524,350 | approved, future | HELMSLEY MEDICAL SIMULATION CENTER | 202530289349100408 |
| 2024 | Global Solidarity Fund New York, NY | D | $1,508,200 | paid | JOB CREATION IN ETHIOPIA | 202530289349100408 |
| 2024 | American Pharmacists Association Foundation Washington, DC | B | $1,502,893 | approved, future | PROJECT IMPACT CGM: EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES | 202530289349100408 |
| 2024 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $1,500,000 | paid | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202530289349100408 |
| 2024 | Schwartzreisman Science Education Center Rehovot (ra) Rehovot | U | $1,500,000 | paid | THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT | 202530289349100408 |
| 2024 | The Broad Institute Inc Cambridge, MA | B | $1,500,000 | paid | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202530289349100408 |
| 2024 | Anthos Home Inc Brooklyn, NY | C | $1,500,000 | approved, future | LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS | 202530289349100408 |
| 2024 | The Broad Institute Inc Cambridge, MA | B | $1,500,000 | paid | NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE | 202530289349100408 |
| 2024 | Cheyenne Regional Medical Center Foundation Cheyenne, WY | B | $1,490,918 | paid | CHEYENNE REGIONAL MEDICAL CENTER WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $1,483,787 | paid | DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D | 202530289349100408 |
| 2024 | Amc Medical Research Bv Amsterdam | U | $1,476,985 | approved, future | A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $1,472,591 | approved, future | CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $1,470,081 | approved, future | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES | 202530289349100408 |
| 2024 | New Venture Fund Washington, DC | B | $1,468,813 | paid | TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,466,732 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,466,731 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Henry J Kaiser Family Foundation San Francisco, CA | B | $1,458,159 | paid | KAISER HEALTH NEWS RURAL HEALTH DESK | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $1,456,556 | approved, future | FAT AS A VILLAIN IN CROHN'S DISEASE. | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $1,454,586 | approved, future | STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL. | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $1,449,344 | paid | PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D) | 202530289349100408 |
| 2024 | A Glimmer of Hope Foundation Austin, TX | C | $1,446,574 | approved, future | EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY | 202530289349100408 |
| 2024 | St Rose Dominican Health Foundation Henderson, NV | U | $1,443,217 | paid | DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Helen Keller International New York, NY | C | $1,441,293 | paid | A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,441,282 | paid | PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $1,421,241 | paid | ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE | 202530289349100408 |
| 2024 | Tel Aviv Sourasky Medical Center - Ichilov Hospital Tel Aviv | U | $1,420,270 | approved, future | GENETICS INSTITUTE AND GENOMICS CENTER | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $1,399,726 | paid | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES | 202530289349100408 |
| 2024 | Children's Mercy Hospital Kansas City, MO | B | $1,399,624 | paid | TYPE 1 DIABETES RAPID LEARNING LAB | 202530289349100408 |
| 2024 | Universite de Geneve Geneve | U | $1,373,247 | paid | PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | New York University School of Medicine New York, NY | C | $1,360,453 | approved, future | TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $1,355,310 | paid | DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES | 202530289349100408 |
| 2024 | The Laniado Kiriat Sanz Hospital Nataniya | U | $1,350,000 | approved, future | NEW MATERNITY FLOOR | 202530289349100408 |
| 2024 | Dreamed Diabetes Ltd Petah Tikva | U | $1,350,000 | paid | INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,348,365 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,348,365 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $1,344,948 | approved, future | FAT AS A VILLAIN IN CROHN'S DISEASE. | 202530289349100408 |
| 2024 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,337,724 | approved, future | HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE | 202530289349100408 |
| 2024 | King's College London London | U | $1,325,562 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | Tel-Aviv University Tel Aviv | D | $1,324,350 | approved, future | HELMSLEY MEDICAL SIMULATION CENTER | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $1,321,210 | approved, future | DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,310,340 | paid | THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,310,183 | approved, future | CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS | 202530289349100408 |
| 2024 | Stichting Health Action International Amsterdam | U | $1,300,026 | approved, future | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV | 202530289349100408 |
| 2024 | Ichud Hatzalah Israel 1221 (ra) Jerusalem | U | $1,300,000 | paid | EMERGENCY FUNDING FOR RESPONSE TO ATTACKS ON ISRAEL | 202530289349100408 |
| 2024 | Bnai Zion Medical Center Haifa | U | $1,300,000 | paid | PURCHASE OF A CT SCANNER FOR BNAI ZION MEDICAL CENTER | 202530289349100408 |
| 2024 | Jerusalem College of Technology Jerusalem | U | $1,300,000 | paid | HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $1,296,918 | approved, future | MINNESOTA FIRST RESPONDER AED PROJECT | 202530289349100408 |
| 2024 | King's College London London | U | $1,296,483 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $1,283,708 | paid | DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLAB. AND REGISTRY | 202530289349100408 |
| 2024 | United States African Development Foundation Washington, DC | U | $1,283,255 | paid | LIVELIHOOD IMPROVEMENT PROGRAM | 202530289349100408 |
| 2024 | The Trevor Project Inc West Hollywood, CA | B | $1,282,735 | approved, future | LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT | 202530289349100408 |
| 2024 | Foundation for Innovative New Diagnostics Find Geneva | D | $1,275,100 | paid | ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT | 202530289349100408 |
| 2024 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,273,764 | approved, future | HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE | 202530289349100408 |
| 2024 | Scripps Health La Jolla, CA | B | $1,262,800 | approved, future | CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS | 202530289349100408 |
| 2024 | The University of Queensland Brisbane | D | $1,261,871 | paid | LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $1,256,044 | approved, future | PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D) | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $1,255,105 | paid | DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Ann & Robert H Lurie Childrens Hospital of Chicago Chicago, IL | B | $1,245,216 | approved, future | IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D | 202530289349100408 |
| 2024 | Stichting Health Action International Amsterdam | U | $1,245,075 | paid | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE III | 202530289349100408 |
| 2024 | Clinton Health Access Initiative Inc Boston, MA | B | $1,243,053 | paid | MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,239,503 | approved, future | IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE | 202530289349100408 |
| 2024 | Nevada Department of Health and Human Services Carson City, NV | U | $1,239,092 | approved, future | NEVADA VIRTUAL CRISIS CARE | 202530289349100408 |
| 2024 | University of Glasgow Court Glasgow | U | $1,231,291 | paid | COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY | 202530289349100408 |
| 2024 | Cambridge University Hospitals Nhs Foundation Trust Cambridge | U | $1,230,080 | paid | THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Nevada Department of Health and Human Services Carson City, NV | U | $1,230,038 | paid | NEVADA VIRTUAL CRISIS CARE | 202530289349100408 |
| 2024 | Regents of University of California Berkeley Berkeley, CA | D | $1,225,929 | paid | DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $1,223,066 | approved, future | PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D) | 202530289349100408 |
| 2024 | Convergent Impact Inc Boulder, CO | B | $1,212,300 | approved, future | COLLABORATIVE ON HOUSING FOR HEALTH | 202530289349100408 |
| 2024 | Stichting Health Action International Amsterdam | U | $1,200,977 | approved, future | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV | 202530289349100408 |
| 2024 | American College of Diabetology Inc Fayetteville, NC | B | $1,200,436 | approved, future | IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS | 202530289349100408 |
| 2024 | Corporation for Supportive Housing New York City, NY | B | $1,200,000 | paid | HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING | 202530289349100408 |
| 2024 | Beyond Type 1 San Mateo, CA | D | $1,200,000 | approved, future | CAPACITY BUILDING SUPPORT | 202530289349100408 |
| 2024 | Beyond Type 1 San Mateo, CA | D | $1,200,000 | approved, future | CAPACITY BUILDING SUPPORT | 202530289349100408 |
| 2024 | Jdrf Australia Sydney | U | $1,196,912 | approved, future | ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,188,316 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,188,316 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Rambam Health Corporation Haifa | D | $1,186,800 | paid | MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $1,180,400 | approved, future | IBD VENTURES ACADEMIC INCUBATOR | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $1,180,400 | paid | IBD VENTURES ACADEMIC INCUBATOR | 202530289349100408 |
| 2024 | Panorama Global Seattle, WA | B | $1,167,087 | paid | PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND | 202530289349100408 |
| 2024 | Clinton Health Access Initiative Inc Boston, MA | B | $1,166,919 | approved, future | IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION | 202530289349100408 |
| 2024 | National Park Foundation Washington, DC | B | $1,163,270 | paid | BERING LAND BRIDGE VISITOR CENTER | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,161,486 | approved, future | PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY | 202530289349100408 |
| 2024 | King's College London London | U | $1,147,254 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | Oakland University Rochester, MI | B | $1,139,629 | approved, future | A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2) | 202530289349100408 |
| 2024 | Uppsala University Hospital Uppsala | U | $1,139,284 | approved, future | IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION | 202530289349100408 |
| 2024 | Hadassah Medical Organization Jerusalem | U | $1,136,000 | paid | CREATING AND EQUIPPING A NEW COMPREHENSIVE DIAGNOSTIC AND INTERVENTIONAL IMAGING CENTER | 202530289349100408 |
| 2024 | The Broad Institute Inc Cambridge, MA | B | $1,129,976 | approved, future | UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS | 202530289349100408 |
| 2024 | Oakland University Rochester, MI | B | $1,129,765 | approved, future | A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2) | 202530289349100408 |
| 2024 | Trustees of Indiana University Bloomington, IN | U | $1,128,685 | paid | MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES | 202530289349100408 |
| 2024 | Foundation for Innovative New Diagnostics Find Geneva | D | $1,118,735 | approved, future | ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT | 202530289349100408 |
| 2024 | Sanford Research Sioux Fall, SD | C | $1,118,635 | approved, future | PLEDGE PHASE 3 | 202530289349100408 |
| 2024 | Tel Aviv Sourasky Medical Center - Ichilov Hospital Tel Aviv | U | $1,118,516 | approved, future | GENETICS INSTITUTE AND GENOMICS CENTER | 202530289349100408 |
| 2024 | The Regents of the University of California Santa Barbara Santa Barbara, CA | U | $1,116,996 | approved, future | EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $1,116,830 | approved, future | DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR | 202530289349100408 |
| 2024 | Share Trust Inc Dover, MA | C | $1,114,361 | paid | BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION | 202530289349100408 |
| 2024 | The University of Manchester Manchester | U | $1,113,915 | paid | A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION | 202530289349100408 |
| 2024 | Universite de Geneve Geneve | U | $1,112,238 | approved, future | PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Research Triangle Institute Research Triangle Park, NC | C | $1,110,288 | approved, future | USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $1,103,070 | paid | MEDICAL EQUIPMENT FOR EMEK MEDICAL CENTER | 202530289349100408 |
| 2024 | Living Goods Oakland, CA | B | $1,100,222 | paid | DIGITIZING COMMUNITY HEALTH | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $1,093,319 | approved, future | ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE | 202530289349100408 |
| 2024 | The Regents of the University of California San Diego La Jolla, CA | C | $1,092,733 | approved, future | THE DRUGGABLE GPCROME IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Renown Health Foundation Reno, NV | B | $1,091,987 | approved, future | RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA | 202530289349100408 |
| 2024 | The Regents of the University of California San Diego La Jolla, CA | C | $1,091,471 | approved, future | THE DRUGGABLE GPCROME IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Sanford Research Sioux Fall, SD | C | $1,086,430 | approved, future | PLEDGE PHASE 3 | 202530289349100408 |
| 2024 | Montana Pediatrics Missoula, MT | C | $1,086,286 | paid | CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $1,085,802 | paid | SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE: FROM GENETIC TO SENESCENT SIGNALS | 202530289349100408 |
| 2024 | The Imperial College of Science Technology and Medicine London | U | $1,081,289 | approved, future | UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE | 202530289349100408 |
| 2024 | King's College London London | U | $1,079,926 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | Catholic Relief Services-Usccb Baltimore, MD | C | $1,073,759 | approved, future | EXPANDING COMMUNITY RECOVERY AND RESILIENCE | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $1,072,041 | paid | DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | King's College London London | U | $1,069,889 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $1,069,498 | approved, future | DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $1,067,400 | paid | TRAINING AWARDS PROGRAM - CLASS OF 2021 | 202530289349100408 |
| 2024 | Beyond Type 1 San Mateo, CA | D | $1,060,000 | paid | CAPACITY BUILDING SUPPORT | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $1,058,738 | approved, future | PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS | 202530289349100408 |
| 2024 | Regents of University of California Berkeley Berkeley, CA | D | $1,054,179 | approved, future | DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,046,486 | approved, future | GPPAD BIOSAMPLE RFP | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $1,045,519 | paid | DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE? | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,044,591 | paid | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,042,232 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,042,232 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $1,038,654 | approved, future | PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS | 202530289349100408 |
| 2024 | The Imperial College of Science Technology and Medicine London | U | $1,032,574 | approved, future | UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $1,031,896 | paid | ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM | 202530289349100408 |
| 2024 | The Regents of the University of California Santa Barbara Santa Barbara, CA | U | $1,027,327 | approved, future | EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $1,027,184 | approved, future | DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $1,025,846 | approved, future | LEVERAGING NEW ULTRA-RAPID INSULINS WITH AID FOR EXERCISE MANAGEMENT WITH T1D | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $1,024,257 | paid | MISSION: LIFELINE STROKE MONTANA AND POST-ACUTE STROKE CARE QUALITY STANDARDS FIELD TESTING | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $1,023,372 | approved, future | IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES) | 202530289349100408 |
| 2024 | Oakland University Rochester, MI | B | $1,019,181 | approved, future | A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2) | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $1,018,620 | approved, future | EDENT1FI | 202530289349100408 |
| 2024 | Sublette County Health Foundation Pinedale, WY | B | $1,017,308 | paid | SUBLETTE COUNTY HOSPITAL DISTRICT RADIOLOGY EQUIPMENT PROJECT | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $1,016,595 | approved, future | COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL | 202530289349100408 |
| 2024 | Medicines Development for Global Health (mdgh) Southbank | U | $1,014,170 | paid | ADVANCING THE FIGHT AGAINST ONCHOCERCIASIS | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $1,009,535 | paid | DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $1,006,687 | approved, future | MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $1,006,531 | paid | MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE | 202530289349100408 |
| 2024 | Project Concern Zambia Limited Lusaka | U | $1,004,026 | approved, future | EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS | 202530289349100408 |
| 2024 | Center for Health Care Strategies Inc Hamilton, NJ | B | $1,002,514 | approved, future | CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $1,000,684 | approved, future | GPPAD COORDINATION CENTER CONTINUATION | 202530289349100408 |
| 2024 | Pennington County Health and Human Services Rapid City, SD | U | $1,000,000 | paid | PENNINGTON COUNTY CRISIS STABILIZATION UNIT | 202530289349100408 |
| 2024 | Gates Philanthropy Partners City of Industry, CA | U | $1,000,000 | approved, future | POLIO ERADICATION FUND SUPPORT | 202530289349100408 |
| 2024 | Avera Mckennan Hospital and University Health Center Sioux Falls, SD | U | $1,000,000 | paid | AVERA BEHAVIORAL HEALTH CENTER EXPANSION | 202530289349100408 |
| 2024 | Pennington County Health and Human Services Rapid City, SD | U | $1,000,000 | approved, future | PENNINGTON COUNTY CRISIS STABILIZATION UNIT | 202530289349100408 |
| 2024 | Fjc New York, NY | B | $1,000,000 | approved, future | THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS | 202530289349100408 |
| 2024 | Gates Philanthropy Partners City of Industry, CA | U | $1,000,000 | approved, future | POLIO ERADICATION FUND SUPPORT | 202530289349100408 |
| 2024 | Gates Philanthropy Partners City of Industry, CA | U | $1,000,000 | paid | POLIO ERADICATION FUND SUPPORT | 202530289349100408 |
| 2024 | Kmr Advancement of Medical Centers Ltd Haifa | U | $1,000,000 | paid | PROPOSAL FOR BUILDING OF PRINCIPAL INFRASTRUCTURE FOR ALL 20 FLOORS OF THE HELMSLEY HEALTH DISCOVERY TOWER | 202530289349100408 |
| 2024 | Trustees and Friends of Agricultural Research at the Volcani Center Rishon Lezion | U | $1,000,000 | paid | PROTECTING FARMERS AND AGRICULTURAL WORKERS ACROSS THE WESTERN NEGEV | 202530289349100408 |
| 2024 | Fjc New York, NY | B | $1,000,000 | paid | THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS | 202530289349100408 |
| 2024 | Corporation for Supportive Housing New York City, NY | B | $1,000,000 | approved, future | HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING | 202530289349100408 |
| 2024 | Fjc New York, NY | B | $1,000,000 | approved, future | THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS | 202530289349100408 |
| 2024 | Stichting Health Action International Amsterdam | U | $998,988 | approved, future | ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV | 202530289349100408 |
| 2024 | University of Pittsburgh Pittsburgh, PA | B | $998,931 | paid | ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS: A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL) | 202530289349100408 |
| 2024 | The Aspen Institute Inc Washington, DC | B | $998,081 | paid | BUILDING VISIONARY AND EFFECTIVE TEAMS TO ACCELERATE PROGRESS AGAINST TYPE 1 DIABETES (T1D) AND OTHER NON-COMMUNICABLE DISEASES (NCDS) | 202530289349100408 |
| 2024 | Jdrf Australia Sydney | U | $997,843 | approved, future | ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $994,996 | approved, future | PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE) | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $994,512 | approved, future | IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES) | 202530289349100408 |
| 2024 | The Sderot Development Foundation Sderot | U | $993,626 | approved, future | SDEROT MEDICAL CENTER | 202530289349100408 |
| 2024 | Convergent Impact Inc Boulder, CO | B | $992,300 | approved, future | COLLABORATIVE ON HOUSING FOR HEALTH | 202530289349100408 |
| 2024 | Galilee Medical Center Nahariya | U | $991,768 | paid | PURCHASING A CT SCANNER FOR GALILEE MEDICAL CENTER | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $989,083 | approved, future | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $988,042 | paid | STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL. | 202530289349100408 |
| 2024 | American College of Diabetology Inc Fayetteville, NC | B | $981,349 | paid | IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS | 202530289349100408 |
| 2024 | The Sheba Fund for Health Services and Research (ra) Ramat Gan | U | $976,000 | paid | EMERGENCY FUNDING FOR EQUIPMENT | 202530289349100408 |
| 2024 | Project Concern Zambia Limited Lusaka | U | $975,702 | paid | EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS | 202530289349100408 |
| 2024 | International Alliance for Diabetes Action Inc Boston, MA | B | $971,684 | approved, future | SEED FUNDING SUPPORT | 202530289349100408 |
| 2024 | The Broad Institute Inc Cambridge, MA | B | $971,014 | approved, future | UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS | 202530289349100408 |
| 2024 | Path Seattle, WA | C | $967,457 | paid | THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $963,282 | approved, future | COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL | 202530289349100408 |
| 2024 | Snv Netherlands Development Organisation Den Haag | U | $962,857 | paid | HEALTHY FUTURE FOR ALL (HF4A) IMPROVING WATER, SANITATION, HYGIENE AND NUTRITION | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $961,620 | paid | DECODING THE CLINICAL IMPACT OF HOST AND MICROBIAL INTESTINAL PROTEOMIC LANDSCAPE IN CROHNS DISEASE | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $947,483 | paid | DECODING PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IMPACTING CLINICAL AND PROGNOSTIC FEATURES IN CROHNS DISEASE | 202530289349100408 |
| 2024 | National Association of School Nurses Inc Silver Spring, MD | B | $946,275 | approved, future | PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT | 202530289349100408 |
| 2024 | Cardiff University Wales | U | $944,873 | paid | T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D | 202530289349100408 |
| 2024 | Cork University Foundation Cork | U | $941,943 | approved, future | ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS | 202530289349100408 |
| 2024 | Joslin Diabetes Center Inc Boston, MA | B | $941,354 | paid | AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES | 202530289349100408 |
| 2024 | Beyond Type 1 San Mateo, CA | D | $940,000 | paid | CAPACITY BUILDING SUPPORT | 202530289349100408 |
| 2024 | Ben-Gurion University of the Negev Beer Sheva | D | $938,641 | paid | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CD | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $934,083 | paid | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT | 202530289349100408 |
| 2024 | Klinikum Der Ludwig-Maximilians-Universitat Munchen Munchen | U | $931,293 | approved, future | FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | National Association of School Nurses Inc Silver Spring, MD | B | $927,791 | approved, future | PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT | 202530289349100408 |
| 2024 | Klinikum Der Ludwig-Maximilians-Universitat Munchen Munchen | U | $925,603 | approved, future | FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $920,802 | approved, future | SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE: FROM GENETIC TO SENESCENT SIGNALS | 202530289349100408 |
| 2024 | University of Western Ontario London | D | $919,293 | paid | ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM | 202530289349100408 |
| 2024 | Southcentral Foundation Anchorage, AL | U | $903,283 | paid | FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM | 202530289349100408 |
| 2024 | The Academic College at Tel-Hai Upper Galilee | U | $900,000 | paid | THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING. | 202530289349100408 |
| 2024 | International Alliance for Diabetes Action Inc Boston, MA | B | $893,663 | approved, future | SEED FUNDING SUPPORT | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $893,092 | paid | PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS | 202530289349100408 |
| 2024 | Cardiff University Cardiff | U | $892,873 | approved, future | T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D | 202530289349100408 |
| 2024 | National Association of School Nurses Inc Silver Spring, MD | B | $891,762 | paid | PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT | 202530289349100408 |
| 2024 | Scripps Health La Jolla, CA | B | $888,800 | approved, future | CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS | 202530289349100408 |
| 2024 | National Committee for Quality Assurance Washington, DC | B | $885,819 | paid | NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT | 202530289349100408 |
| 2024 | University of Massachusetts Medical School Worcester, MA | U | $881,959 | paid | DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202530289349100408 |
| 2024 | University of Melbourne Victoria | D | $880,551 | paid | ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR | 202530289349100408 |
| 2024 | Stichting Access to Medicine Foundation Amsterdam | U | $875,000 | paid | EXPANDING ACCESS TO T1D CARE | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $871,217 | approved, future | HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE | 202530289349100408 |
| 2024 | Path Seattle, WA | C | $871,123 | approved, future | THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE | 202530289349100408 |
| 2024 | National Park Foundation Washington, DC | B | $869,558 | paid | LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $869,476 | approved, future | ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM | 202530289349100408 |
| 2024 | United States Fund for Unicef New York, NY | U | $869,232 | approved, future | ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS | 202530289349100408 |
| 2024 | New York City Health and Hospitals Corporation New York, NY | C | $867,832 | paid | EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC | 202530289349100408 |
| 2024 | University Hospitals Health System Inc Cleveland, OH | U | $866,199 | approved, future | TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS | 202530289349100408 |
| 2024 | Weill Medical College of Cornell University New York, NY | U | $863,618 | approved, future | TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE | 202530289349100408 |
| 2024 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $855,546 | approved, future | EXPANSION OF THE DANATECH PLATFORM | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $855,018 | paid | EDENT1FI | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $851,645 | approved, future | DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE? | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $850,098 | approved, future | HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE | 202530289349100408 |
| 2024 | Mainehealth Portland, ME | U | $848,894 | approved, future | TRANSFORMING RURAL DIABETES CARE IN MAINE | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $836,979 | paid | INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $835,639 | approved, future | DIABETESWISE FOR EXERCISE | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $835,489 | approved, future | PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE) | 202530289349100408 |
| 2024 | The Regents of the University of California Santa Barbara Santa Barbara, CA | U | $832,906 | paid | EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Association of Diabetes Care & Education Specialists Chicago, IL | B | $831,327 | paid | EXPANSION OF THE DANATECH PLATFORM | 202530289349100408 |
| 2024 | Research Triangle Institute Research Triangle Park, NC | C | $826,376 | approved, future | USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY | 202530289349100408 |
| 2024 | King's College London London | U | $825,146 | approved, future | PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY) | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $820,911 | approved, future | DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE? | 202530289349100408 |
| 2024 | Southcentral Foundation Anchorage, AK | B | $818,171 | approved, future | FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM | 202530289349100408 |
| 2024 | Benaroya Research Institute at Virginia Mason Seattle, WA | B | $809,757 | paid | LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $809,568 | approved, future | IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $808,734 | approved, future | DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS? | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $805,385 | approved, future | EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE) | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $805,382 | paid | TRAINING AND MENTORSHIP PROGRAMS | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $805,382 | approved, future | TRAINING AND MENTORSHIP PROGRAMS | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $805,382 | approved, future | TRAINING AND MENTORSHIP PROGRAMS | 202530289349100408 |
| 2024 | Corporation for Supportive Housing New York City, NY | B | $800,000 | approved, future | HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING | 202530289349100408 |
| 2024 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $797,851 | paid | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE: THE OPTIMIZE TRIAL | 202530289349100408 |
| 2024 | Beth Israel Deaconess Medical Center Inc Boston, MA | B | $797,851 | approved, future | PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE: THE OPTIMIZE TRIAL | 202530289349100408 |
| 2024 | Solidaridad Network Foundation Limited Lusaka | U | $795,998 | paid | HOOVES FOR SUSTAINABILITY (H4S) | 202530289349100408 |
| 2024 | Yale University New Haven, CT | U | $792,237 | paid | TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE | 202530289349100408 |
| 2024 | The University of Chicago Chicago, IL | U | $784,751 | paid | DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND | 202530289349100408 |
| 2024 | United States Fund for Unicef New York, NY | U | $784,421 | paid | ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS | 202530289349100408 |
| 2024 | De la Salle Solidarieta Internazionale - Ets Rome | U | $784,080 | paid | EXPAND DEVELOPMENT OF LASALLIAN UNIVERSITY OF AFRICA | 202530289349100408 |
| 2024 | King's College London London | U | $781,151 | approved, future | PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY) | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $779,716 | approved, future | PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE, AN ADAPTATION FOR NYCS COMMUNITY MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS. | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $778,887 | paid | GPPAD COORDINATION CENTER CONTINUATION | 202530289349100408 |
| 2024 | King's College London London | U | $778,535 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | Barzilai Medical Center Ashkelon | U | $776,930 | paid | EMERGENCY FUNDING FOR EQUIPMENT | 202530289349100408 |
| 2024 | Stichting Pharmaccess International Amsterdam | U | $774,350 | paid | SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $770,816 | paid | COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY | 202530289349100408 |
| 2024 | Ben-Gurion University of the Negev Beer Sheva | D | $765,436 | approved, future | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CROHN'S DISEASE. | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $759,619 | paid | THE MELODY TRIAL: MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHN'S DISEASE | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $758,218 | approved, future | DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | University of Florida Gainesville, FL | U | $757,160 | approved, future | UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC): A NATIONAL NEEDS ASSESSMENT | 202530289349100408 |
| 2024 | University of Western Ontario London | D | $756,873 | approved, future | ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM | 202530289349100408 |
| 2024 | The Sheba Fund for Health Services and Research (ra) Ramat Gan | U | $756,699 | approved, future | ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD) | 202530289349100408 |
| 2024 | National Committee for Quality Assurance Washington, DC | B | $753,478 | approved, future | NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT | 202530289349100408 |
| 2024 | Tzafon Medical Center Tiberias | U | $752,574 | paid | VASCULAR ANGIOGRAPHY INSTITUTE | 202530289349100408 |
| 2024 | Mass General Brigham for the Massachusetts General Hospital Boston, MA | U | $752,326 | paid | WIRELESS INFRARED IMAGING CAPSULE FOR PINPOINTING INFLAMMATION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Ghana Rural Integrated Development Milton | D | $751,636 | paid | LEYAATA HOSPITAL MEDICAL HOUSING | 202530289349100408 |
| 2024 | Johns Hopkins University Baltimore, MD | U | $750,000 | approved, future | ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE | 202530289349100408 |
| 2024 | Institute for Community Living Inc New York City, NY | B | $749,790 | paid | PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT | 202530289349100408 |
| 2024 | Institute for Community Living Inc New York City, NY | B | $749,790 | approved, future | PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT | 202530289349100408 |
| 2024 | Institute for Community Living Inc New York City, NY | B | $749,790 | approved, future | PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT | 202530289349100408 |
| 2024 | Oregon Health & Science University Portland, OR | U | $749,644 | paid | NICH BAY AREA EXPANSION | 202530289349100408 |
| 2024 | Americares Foundation Inc Stamford, CT | C | $749,599 | paid | MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS | 202530289349100408 |
| 2024 | Rambam Health Corporation Haifa | D | $746,990 | approved, future | MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $745,207 | paid | GPPAD COORDINATION CENTER CONTINUATION | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $744,245 | approved, future | ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS | 202530289349100408 |
| 2024 | Johns Hopkins University Baltimore, MD | U | $742,901 | approved, future | DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING | 202530289349100408 |
| 2024 | University of Florida Gainesville, FL | U | $741,600 | paid | UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC): A NATIONAL NEEDS ASSESSMENT | 202530289349100408 |
| 2024 | Oakland University Rochester, MI | B | $738,313 | paid | A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 1) | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $733,694 | approved, future | THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $726,752 | approved, future | DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS? | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $725,157 | approved, future | DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $723,366 | paid | POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA | 202530289349100408 |
| 2024 | University Medical Center of Southern Nevada Las Vegas, NV | U | $719,072 | paid | DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $719,051 | approved, future | ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $718,215 | approved, future | EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - ANOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Iowa Iowa City, IA | U | $714,411 | approved, future | SIMULATION IN MOTION IOWA (SIM-IA) | 202530289349100408 |
| 2024 | International Alliance for Diabetes Action Inc Boston, MA | B | $714,053 | paid | SEED FUNDING SUPPORT | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $713,088 | paid | EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - ANOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $712,850 | paid | ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS | 202530289349100408 |
| 2024 | University Hospitals Health System Inc Cleveland, OH | U | $707,339 | paid | TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS | 202530289349100408 |
| 2024 | University of Kansas Center for Research Inc Lawrence, KS | B | $706,324 | approved, future | PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D | 202530289349100408 |
| 2024 | Mass General Brigham for the Massachusetts General Hospital Boston, MA | U | $705,894 | paid | CROHN'S DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION AND BETTER TREATMENT | 202530289349100408 |
| 2024 | University of Notre Dame du Lac Notre Dame, ID | U | $705,510 | approved, future | DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $705,194 | paid | FEASIBILITY PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH T1D AND T2D | 202530289349100408 |
| 2024 | The Sheba Fund for Health Services and Research (ra) Ramat Gan | U | $704,764 | paid | ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD) | 202530289349100408 |
| 2024 | The Association for the Resident and Community in Ramat Hanegev Ramat Hanegev | U | $699,190 | approved, future | RAMAT HANEGEV SENIOR CITIZEN CENTER | 202530289349100408 |
| 2024 | Alyn Hospital - Rehabilitation Center for Children and Youth Jerusalem | U | $694,034 | paid | ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH | 202530289349100408 |
| 2024 | The University of Manchester Manchester | U | $692,839 | approved, future | A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $692,073 | approved, future | UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $688,466 | approved, future | THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND) | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $686,820 | approved, future | SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY | 202530289349100408 |
| 2024 | Stichting Pharmaccess International Amsterdam | U | $686,565 | approved, future | SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY | 202530289349100408 |
| 2024 | Children's Hospital Los Angeles Los Angeles, CA | U | $684,686 | approved, future | BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $682,311 | approved, future | MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC) | 202530289349100408 |
| 2024 | Children's Hospital Los Angeles Los Angeles, CA | U | $679,025 | paid | BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE | 202530289349100408 |
| 2024 | University Hospitals Health System Inc Cleveland, OH | U | $677,700 | approved, future | TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $676,014 | paid | CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION | 202530289349100408 |
| 2024 | Sheridan County Memorial Hospital Foundation Sheridan, WY | B | $675,676 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $672,617 | paid | PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE FOR NYCS MOST VULNERABLE MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS. | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $672,500 | paid | DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED) | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $672,028 | approved, future | EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM | 202530289349100408 |
| 2024 | University of Notre Dame du Lac Notre Dame, ID | U | $671,881 | approved, future | GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $669,554 | paid | UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Care-for-Rare Foundation Munich | U | $667,252 | approved, future | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $667,139 | paid | THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $666,216 | paid | NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI) | 202530289349100408 |
| 2024 | University of Florida Gainesville, FL | U | $665,910 | approved, future | HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $665,654 | paid | NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI) | 202530289349100408 |
| 2024 | Cork University Foundation Cork | U | $663,503 | approved, future | ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS | 202530289349100408 |
| 2024 | Cambridge University Hospitals Nhs Foundation Trust Cambridge | U | $657,605 | approved, future | THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Care-for-Rare Foundation Munich | U | $655,603 | paid | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES | 202530289349100408 |
| 2024 | Oregon Health & Science University Portland, OR | U | $654,234 | paid | NICH BAY AREA EXPANSION | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $650,000 | approved, future | EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $650,000 | paid | DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $648,749 | paid | IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $645,000 | approved, future | DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED) | 202530289349100408 |
| 2024 | Cork University Foundation Cork | U | $642,744 | paid | ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS | 202530289349100408 |
| 2024 | University of Wyoming Foundation Laramie, WY | B | $641,903 | paid | ULTRASOUND TRAINING INITIATIVE IN WYOMING | 202530289349100408 |
| 2024 | Bipartisan Policy Center Inc Washington, DC | B | $633,819 | approved, future | STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES | 202530289349100408 |
| 2024 | T1d Exchange Inc Boston, MA | U | $633,709 | approved, future | EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY | 202530289349100408 |
| 2024 | Cardiff University Cardiff | U | $632,664 | approved, future | T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D | 202530289349100408 |
| 2024 | Reachanother Foundation Bend, OR | U | $627,684 | approved, future | EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $626,728 | approved, future | APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Center for Health Care Strategies Inc Hamilton, NJ | B | $626,707 | approved, future | CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN | 202530289349100408 |
| 2024 | Guardian Org Foundation Washington, DC | B | $625,000 | paid | A GROWING CRISIS: NON-COMMUNICABLE DISEASES, AN INDEPENDENT JOURNALISM SERIES BY THE GUARDIAN | 202530289349100408 |
| 2024 | Bipartisan Policy Center Inc Washington, DC | B | $622,296 | paid | STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES | 202530289349100408 |
| 2024 | National Committee for Quality Assurance Washington, DC | B | $621,487 | approved, future | NCQA DIABETES RECOGNITION PROGRAM REFRESH & DIABETES MEASURE DEVELOPMENT | 202530289349100408 |
| 2024 | Billings Clinic Foundation Billings, MT | B | $620,341 | paid | EXPANDING ECMO SERVICES AT BILLINGS CLINIC | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $620,243 | paid | EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE) | 202530289349100408 |
| 2024 | Seattle Children's Hospital Seattle, WA | U | $616,923 | approved, future | EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4) | 202530289349100408 |
| 2024 | New York City Health and Hospitals Corporation New York, NY | C | $614,668 | approved, future | EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC | 202530289349100408 |
| 2024 | Bipartisan Policy Center Inc Washington, DC | B | $609,887 | approved, future | STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES | 202530289349100408 |
| 2024 | Seattle Children's Hospital Seattle, WA | U | $609,141 | approved, future | EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4) | 202530289349100408 |
| 2024 | Saint Louis University Saint Louis, MI | U | $608,523 | approved, future | IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Saint Louis University Saint Louis, MO | B | $608,000 | paid | IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | University of Western Ontario London | D | $606,448 | approved, future | ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM | 202530289349100408 |
| 2024 | Yale University New Haven, CT | U | $605,522 | approved, future | TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE | 202530289349100408 |
| 2024 | Seattle Children's Hospital Seattle, WA | U | $602,243 | paid | EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4) | 202530289349100408 |
| 2024 | Ichud Hatzalah Israel 1221 (ra) Jerusalem | U | $600,000 | paid | PROVIDING SUPPORT FOR EMERGENCY PREPAREDNESS | 202530289349100408 |
| 2024 | Campbell County Hospital District Gillette, WY | B | $599,884 | paid | CAMPBELL COUNTY HEALTH ULTRASOUND PROJECT | 202530289349100408 |
| 2024 | Yale University New Haven, CT | U | $599,035 | approved, future | TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $598,309 | approved, future | SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY | 202530289349100408 |
| 2024 | Memorial Hospital of Carbon County Rawlins, WY | U | $598,152 | paid | MEMORIAL HOSPITAL OF CARBON COUNTY ULTRASOUND EQUIPMENT | 202530289349100408 |
| 2024 | Splash International Seattle, WA | B | $597,840 | paid | WASH IN SCHOOLS FOR EVERYONE | 202530289349100408 |
| 2024 | Mainehealth Portland, ME | U | $596,795 | approved, future | TRANSFORMING RURAL DIABETES CARE IN MAINE | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $595,677 | paid | APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $588,266 | paid | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $588,266 | paid | SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Association Sante Diabete Grenoble | U | $587,221 | approved, future | STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS | 202530289349100408 |
| 2024 | Association Sante Diabete Grenoble | U | $587,221 | approved, future | STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $587,152 | approved, future | DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT | 202530289349100408 |
| 2024 | Breaking Ground Housing Development Fund Corporation New York, NY | B | $585,924 | approved, future | PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $585,172 | approved, future | STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL. | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $583,311 | paid | DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS? | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $581,625 | paid | GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES | 202530289349100408 |
| 2024 | University of Kansas Center for Research Inc Lawrence, KS | B | $579,370 | approved, future | PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D | 202530289349100408 |
| 2024 | The Sonia Nabeta Foundation Inc Long Island City, NY | C | $578,470 | approved, future | WORLD OF WARRIORS | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $575,810 | paid | ASK THE EXPERTS | 202530289349100408 |
| 2024 | Johns Hopkins University Baltimore, MD | U | $571,287 | approved, future | TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS | 202530289349100408 |
| 2024 | Joslin Diabetes Center Inc Boston, MA | B | $569,990 | approved, future | AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES | 202530289349100408 |
| 2024 | University of Florida Gainesville, FL | U | $569,086 | approved, future | HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION | 202530289349100408 |
| 2024 | The Regents of the University of California Los Angeles Los Angeles, CA | U | $568,851 | paid | GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Johns Hopkins University Baltimore, MD | U | $568,782 | paid | TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS | 202530289349100408 |
| 2024 | The Regents of the University of California Los Angeles Los Angeles, CA | U | $568,027 | approved, future | GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Breaking Ground Housing Development Fund Corporation New York, NY | B | $567,155 | approved, future | PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING | 202530289349100408 |
| 2024 | Johns Hopkins University Baltimore, MD | U | $567,091 | paid | DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING | 202530289349100408 |
| 2024 | Baylor College of Medicine Houston, TX | B | $566,062 | paid | PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE | 202530289349100408 |
| 2024 | Crohn's and Colitis Canada Toronto | U | $562,426 | paid | IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA | 202530289349100408 |
| 2024 | Memorial Hospital of Converse County Douglas, WY | U | $559,262 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Albert Einstein College of Medicine Bronx, NY | B | $556,499 | paid | PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The Hospital for Sick Children Toronto | U | $555,480 | approved, future | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES | 202530289349100408 |
| 2024 | Jdrf International New York, NY | U | $555,046 | paid | AUTOIMMUNITY SCREENING FOR KIDS (ASK) PROGRAM TRANSITION TOWARDS A SUSTAINABLE SCREENING FOR T1D AND CELIAC DISEASE IN COLORADO (ASK RENEWAL 2022) | 202530289349100408 |
| 2024 | Memorial Hospital of Sweetwater County Foundation Rock Springs, WY | C | $551,594 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Ivinson Memorial Hospital Laramie, WY | C | $550,348 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Community Service Society of New York (css) New York, NY | C | $550,000 | paid | KEEP NEW YORK COVERED (KNYC) | 202530289349100408 |
| 2024 | The Hospital for Sick Children Toronto | U | $548,276 | paid | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES | 202530289349100408 |
| 2024 | Baylor College of Medicine Houston, TX | B | $547,540 | approved, future | PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE | 202530289349100408 |
| 2024 | The Regents of the University of California San Diego La Jolla, CA | C | $545,759 | paid | MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN | 202530289349100408 |
| 2024 | Alliance of Community Health Plans Foundation Inc Washington, DC | B | $539,349 | approved, future | COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION | 202530289349100408 |
| 2024 | Stichting Pharmaccess International Amsterdam | U | $538,692 | approved, future | SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY | 202530289349100408 |
| 2024 | University at Buffalo Pediatric Associates P C Buffalo, NY | D | $537,700 | approved, future | FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS | 202530289349100408 |
| 2024 | Federal Institute of Technology Zurich Ethz Zurich | U | $536,228 | paid | SPATIAL BIOLOGY OF CROHNS COLITIS | 202530289349100408 |
| 2024 | Montana Pediatrics Missoula, MT | C | $536,186 | approved, future | CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D | 202530289349100408 |
| 2024 | Baylor College of Medicine Houston, TX | B | $532,841 | paid | PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE | 202530289349100408 |
| 2024 | King's College London London | U | $531,295 | paid | IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $526,471 | approved, future | THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A) | 202530289349100408 |
| 2024 | Dartmouth- Hitchcock Clinic Lebanon, NH | B | $525,177 | approved, future | CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM | 202530289349100408 |
| 2024 | Baylor College of Medicine Houston, TX | B | $520,313 | paid | PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $519,768 | approved, future | THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION | 202530289349100408 |
| 2024 | Chancellor Masters & Scholars of the University of Oxford Oxford | D | $515,981 | approved, future | ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA | 202530289349100408 |
| 2024 | The Sonia Nabeta Foundation Inc Long Island City, NY | C | $514,210 | approved, future | WORLD OF WARRIORS | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $513,936 | approved, future | EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY | 202530289349100408 |
| 2024 | Dartmouth- Hitchcock Clinic Lebanon, NH | B | $509,790 | paid | CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM | 202530289349100408 |
| 2024 | University of Birmingham Birmingham | U | $506,886 | paid | CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $506,760 | approved, future | IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES) | 202530289349100408 |
| 2024 | Friends of the Israel Defense Forces New York, NY | B | $503,200 | paid | IMPACT! SCHOLARSHIP PROGRAM | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $502,750 | approved, future | ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3) | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $502,750 | paid | ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3) | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $502,750 | approved, future | ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3) | 202530289349100408 |
| 2024 | Acumen America LLC New York, NY | U | $502,312 | paid | SUPPLEMENTAL SUPPORT TO ADDRESS SOCIAL DETERMINANTS OF HEALTH FOR PEOPLE WITH INSULIN REQUIRING DIABETES | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $501,000 | approved, future | T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $501,000 | approved, future | T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $501,000 | paid | T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES | 202530289349100408 |
| 2024 | City Parks Foundation New York, NY | B | $500,000 | approved, future | NYC GREEN FUND | 202530289349100408 |
| 2024 | Critical Path Institute Tucson, AZ | B | $500,000 | approved, future | TRANSLATIONAL THERAPEUTICS ACCELERATOR: DEVELOPING KINASE INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE TO TREAT T1D | 202530289349100408 |
| 2024 | City Parks Foundation New York, NY | B | $500,000 | approved, future | NYC GREEN FUND | 202530289349100408 |
| 2024 | Yitzhak Shamir Medical Center Tzrifin | U | $500,000 | paid | SHAMIR UNDERGROUND EMERGENCY HOSPITAL EQUIPMENT | 202530289349100408 |
| 2024 | Jdrf International New York, NY | U | $500,000 | paid | JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES | 202530289349100408 |
| 2024 | Ziv Medical Center Zefat Zefat | U | $500,000 | paid | EMERGENCY EQUIPMENT FOR ZIV MEDICAL CENTER | 202530289349100408 |
| 2024 | Jerusalem College of Technology Jerusalem | U | $500,000 | paid | EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY. | 202530289349100408 |
| 2024 | Anthos Home Inc Brooklyn, NY | C | $500,000 | approved, future | LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS | 202530289349100408 |
| 2024 | Alliance of Community Health Plans Foundation Inc Washington, DC | B | $500,000 | paid | COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING (CGM) | 202530289349100408 |
| 2024 | The Binyamin Fund Inc Cedarhurst, NY | C | $500,000 | paid | EMERGENCY PREPAREDNESS FOR COMMUNITIES IN BINYAMIN REGIONAL COUNCIL | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $500,000 | paid | CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2) | 202530289349100408 |
| 2024 | Alliance of Community Health Plans Foundation Inc Washington, DC | B | $500,000 | approved, future | COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION | 202530289349100408 |
| 2024 | Mass General Brigham for the Brigham and Women's Hospital Boston, MA | U | $499,459 | paid | INVESTIGATION OF ANTI-GM-CSF AUTOANTIBODIES AS A DISEASE DETERMINANT IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $496,512 | paid | DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS | 202530289349100408 |
| 2024 | Albert Einstein College of Medicine Bronx, NY | B | $494,612 | paid | PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The Scripps Research Institute La Jolla, CA | B | $494,231 | paid | TRANSLATION OF MICROBIOTA MECHANISMS ON NOD2 FOR CROHNS DISEASE THERAPIES | 202530289349100408 |
| 2024 | Maccabi Healthcare Services Tel Aviv | U | $492,958 | paid | URGENT PROCUREMENT OF MEDICAL EQUIPMENT FOR WOUNDED SOLDIERS AND CIVILIANS | 202530289349100408 |
| 2024 | University of Melbourne Victoria | D | $490,922 | approved, future | USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $490,041 | approved, future | COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $488,553 | approved, future | THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND) | 202530289349100408 |
| 2024 | Washington University Saint Louis, MI | U | $488,300 | approved, future | CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE | 202530289349100408 |
| 2024 | Billings Clinic Foundation Billings, MT | B | $485,826 | approved, future | EXPANDING ECMO SERVICES AT BILLINGS CLINIC | 202530289349100408 |
| 2024 | Georgia Tech Research Corporation Atlanta, GA | C | $485,617 | paid | LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE | 202530289349100408 |
| 2024 | Georgia Tech Research Corporation Atlanta, GA | C | $485,616 | approved, future | LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE | 202530289349100408 |
| 2024 | The Sonia Nabeta Foundation Inc Long Island City, NY | C | $482,110 | approved, future | WORLD OF WARRIORS | 202530289349100408 |
| 2024 | Georgia Tech Research Corporation Atlanta, GA | C | $480,848 | paid | LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Birmingham Birmingham | U | $479,888 | approved, future | CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Johnson County Hospital District Buffalo, WY | B | $476,613 | paid | JOHNSON COUNTY HEALTHCARE CENTER ULTRASOUND EQUIPMENT | 202530289349100408 |
| 2024 | Association Sante Diabete Grenoble | U | $475,984 | paid | IMPROVE THE MANAGEMENT OF DIABETES (ESPECIALLY T1D) AND THE SUPPORT TO PEOPLE AFFECTED BY THE DISEASE IN BURKINA FASO, MALI, AND THE UNION OF COMOROS | 202530289349100408 |
| 2024 | University of Massachusetts Medical School Worcester, MA | U | $473,409 | approved, future | DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS | 202530289349100408 |
| 2024 | The Regents of the University of California San Diego La Jolla, CA | C | $471,131 | approved, future | MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN | 202530289349100408 |
| 2024 | Solidaridad Network Foundation Limited Lusaka | U | $468,562 | approved, future | HOOVES FOR SUSTAINABILITY (H4S) | 202530289349100408 |
| 2024 | West Park Hospital District Cody, WY | U | $466,486 | paid | CODY REGIONAL HEALTH ULTRASOUND PROJECT | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $463,512 | approved, future | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES | 202530289349100408 |
| 2024 | The Regents of the University of California at Irvine Irvine, CA | C | $461,893 | paid | DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | University of Wyoming Foundation Laramie, WY | B | $458,857 | approved, future | ULTRASOUND TRAINING INITIATIVE IN WYOMING | 202530289349100408 |
| 2024 | University of Wyoming Foundation Laramie, WY | B | $458,857 | approved, future | ULTRASOUND TRAINING INITIATIVE IN WYOMING | 202530289349100408 |
| 2024 | Regents of the University of Michigan Ann Arbor, MI | C | $458,831 | approved, future | HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS | 202530289349100408 |
| 2024 | Yehuda Abarbanel Government Hospital Bat Yam | U | $454,960 | approved, future | MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $453,311 | paid | IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES) | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $452,465 | paid | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES | 202530289349100408 |
| 2024 | Universite Catholique de Louvain Louvainlaneuve | U | $450,921 | paid | SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM | 202530289349100408 |
| 2024 | Ben-Gurion University of the Negev Beer Sheva | D | $450,000 | paid | EMERGENCY PREPAREDNESS FOR BEN GURION UNIVERSITY OF THE NEGEV | 202530289349100408 |
| 2024 | Billings Clinic Foundation Billings, MT | B | $449,629 | approved, future | EXPANDING ECMO SERVICES AT BILLINGS CLINIC | 202530289349100408 |
| 2024 | King's College London London | U | $447,521 | paid | RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE. | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $444,246 | paid | HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $439,601 | approved, future | ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES | 202530289349100408 |
| 2024 | Crook County Medical Services District Sundance, WY | C | $437,000 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Medicines for Humanity Inc Rockland, MA | B | $436,472 | paid | MAI MBELEKI II EXPANSION | 202530289349100408 |
| 2024 | Innodia Leuven | U | $434,183 | approved, future | INNODIA NONPROFIT LAUNCH | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $433,333 | approved, future | IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS | 202530289349100408 |
| 2024 | Georgetown University Washington, DC | B | $432,998 | approved, future | ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION | 202530289349100408 |
| 2024 | The Association for the Resident and Community in Ramat Hanegev Ramat Hanegev | U | $432,000 | paid | EMERGENCY PREPAREDNESS FOR COMMUNITIES IN THE RAMAT HANEGEV COUNCIL REGION OF SOUTHERN ISRAEL | 202530289349100408 |
| 2024 | University of Bristol Bristol | U | $431,779 | approved, future | TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $429,712 | paid | MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Cincinnati Cincinnati, OH | B | $429,700 | approved, future | STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $429,646 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Trustees of Indiana University Bloomington, IN | U | $426,380 | paid | COLLABORATIVE EFFORT TO VALIDATE MICRORNA AS BIOMARKERS OF T1D | 202530289349100408 |
| 2024 | Aphp St Antoine Hospital Paris | U | $421,681 | approved, future | FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE) | 202530289349100408 |
| 2024 | Federal Institute of Technology Zurich Ethz Zurich | U | $421,278 | approved, future | SPATIAL BIOLOGY OF CROHNS COLITIS | 202530289349100408 |
| 2024 | Middle East Media and Research Institute Inc Washington, DC | B | $420,000 | paid | HIRING ADDITIONAL TRANSLATORS/ANALYSTS | 202530289349100408 |
| 2024 | Georgetown University Washington, DC | B | $418,301 | paid | ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $418,217 | paid | CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM | 202530289349100408 |
| 2024 | University of Cincinnati Cincinnati, OH | B | $416,500 | paid | STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE | 202530289349100408 |
| 2024 | University of Cincinnati Cincinnati, OH | B | $416,500 | approved, future | STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE | 202530289349100408 |
| 2024 | Yale University New Haven, CT | U | $414,595 | paid | EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $413,871 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $413,263 | approved, future | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $413,258 | paid | IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE | 202530289349100408 |
| 2024 | Medical University of South Carolina Charleston, SC | C | $412,500 | paid | ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Australasian Gastro Intestinal Research Foundation Ltd Fitzroy | U | $410,936 | paid | FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY. | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $410,774 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $407,932 | approved, future | COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL | 202530289349100408 |
| 2024 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $407,000 | paid | ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS | 202530289349100408 |
| 2024 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $407,000 | approved, future | ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS | 202530289349100408 |
| 2024 | University of Melbourne Victoria | D | $405,066 | approved, future | USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $404,688 | paid | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202530289349100408 |
| 2024 | Regents of the University of Michigan Ann Arbor, MI | C | $403,877 | paid | HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $402,980 | approved, future | DIABDOCS NATIONAL K12: SUPPLEMENT | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $402,980 | paid | DIABDOCS NATIONAL K12: SUPPLEMENT | 202530289349100408 |
| 2024 | Genome Research Limited for the Wellcome Sanger Institute Cambridge | U | $402,672 | approved, future | SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Children's Hospital Medical Center Cincinnati, OH | B | $402,142 | paid | COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL | 202530289349100408 |
| 2024 | The City of Hope Duarte, CA | U | $400,000 | paid | THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202530289349100408 |
| 2024 | Simulation in Motion Montana Inc Helena, MT | B | $400,000 | paid | SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY | 202530289349100408 |
| 2024 | Northern Westchester Hospital Association Mount Kisco, NY | C | $400,000 | approved, future | EMERGENCY DEPARTMENT RAPID ACCESS EXPANSION | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $399,368 | approved, future | 2022-2024 TYPE 1 DIABETES CAMP INITIATIVE | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $399,368 | paid | 2022-2024 TYPE 1 DIABETES CAMP INITIATIVE | 202530289349100408 |
| 2024 | New Destiny Housing Corporation New York, NY | B | $398,456 | paid | PILOTING AFTERCARE INTERVENTIONTO IMPROVE HOUSING AND HEALTH STABILITYFOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS | 202530289349100408 |
| 2024 | Genome Research Limited for the Wellcome Sanger Institute Cambridge | U | $397,123 | paid | SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Wind River Family and Community Health Care System Arapahoe, WY | U | $391,802 | paid | WYOMING ULTRASOUND REVITALIZATION INITIATIVE | 202530289349100408 |
| 2024 | The Imperial College of Science Technology and Medicine London | U | $391,212 | approved, future | IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $387,615 | approved, future | MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Washington Seattle, WA | B | $387,576 | approved, future | DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4 | 202530289349100408 |
| 2024 | University Medical Center of Southern Nevada Las Vegas, NV | U | $387,094 | approved, future | DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA | 202530289349100408 |
| 2024 | Mayo Clinic Rochester, MN | U | $385,906 | approved, future | FEASIBILITY OF OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS: A PILOT ANIMAL FEASIBILITY STUDY | 202530289349100408 |
| 2024 | King's College London London | U | $384,292 | approved, future | RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE. | 202530289349100408 |
| 2024 | The Imperial College of Science Technology and Medicine London | U | $380,592 | paid | IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $379,458 | approved, future | POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $379,194 | paid | DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $379,100 | paid | THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND) | 202530289349100408 |
| 2024 | University of Washington Seattle, WA | B | $378,764 | paid | DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4 | 202530289349100408 |
| 2024 | Minnesota Rural Health Association Henning, MN | C | $378,700 | approved, future | SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $375,484 | approved, future | ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS | 202530289349100408 |
| 2024 | Region Hovedstaden Hillerod | U | $375,228 | approved, future | CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES? | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $375,221 | paid | DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CD. USE-IT: A PROSPECTIVE, MULTICENTER STUDY | 202530289349100408 |
| 2024 | Crohn's and Colitis Canada Toronto | U | $374,912 | approved, future | IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $374,591 | paid | MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE | 202530289349100408 |
| 2024 | Children's Hospital Corporation Boston, MA | C | $374,591 | paid | MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Notre Dame du Lac Notre Dame, IN | U | $373,873 | paid | GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES | 202530289349100408 |
| 2024 | The City of Hope Duarte, CA | U | $371,800 | approved, future | CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY | 202530289349100408 |
| 2024 | King's College London London | U | $369,984 | approved, future | MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III | 202530289349100408 |
| 2024 | Regents of the University of Michigan Ann Arbor, MI | C | $369,880 | paid | USING NATURAL LANGUAGE PROCESSING OF CLINICAL DOCUMENTATION TO IMPROVE PERSONALIZATION OF CARE IN CROHN'S DISEASE | 202530289349100408 |
| 2024 | The City of Hope Duarte, CA | U | $368,500 | approved, future | CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY | 202530289349100408 |
| 2024 | Aphp St Antoine Hospital Paris | U | $367,129 | paid | FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE) | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $364,763 | paid | LONG-TERM RESPONSES TO SARS-COV-2 VACCINATION IN A DIVERSE INFLAMMATORY BOWEL DISEASE POPULATION: A MULTI-OMIC STUDY | 202530289349100408 |
| 2024 | Natural Areas Conservancy Inc New York, NY | B | $363,328 | approved, future | ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3) | 202530289349100408 |
| 2024 | Hebrew University of Jerusalem Jerusalem | D | $362,703 | paid | METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Wyoming Community Foundation Laramie, WY | B | $361,581 | paid | ENHANCING ULTRASOUND CAPABILITIES IN WYOMING | 202530289349100408 |
| 2024 | Uppsala University Hospital Uppsala | U | $360,374 | approved, future | IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION | 202530289349100408 |
| 2024 | University of Bristol Bristol | U | $358,900 | approved, future | TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY | 202530289349100408 |
| 2024 | Parker Institute for Cancer Immunotherapy San Francisco, CA | B | $358,140 | approved, future | UNDERSTANDING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES. | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $357,597 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY | 202530289349100408 |
| 2024 | University of Cambridge Oxford | U | $353,223 | approved, future | CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2) | 202530289349100408 |
| 2024 | The Nature Conservancy Arlington, VA | B | $352,196 | paid | FUTURE FOREST NYC PHASE III | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $351,258 | paid | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Uptime Global Oxford | U | $350,000 | paid | RESULTS-BASED SAFE WATER SERVICES | 202530289349100408 |
| 2024 | Mineral County Hospital District Hawthorne, NV | U | $350,000 | paid | USDA COMMUNITY FACILITY DIRECT LOAN PROGRAM APPLICATION | 202530289349100408 |
| 2024 | Ichud Hatzalah Israel 1221 (ra) Jerusalem | U | $350,000 | paid | PROVIDING SUPPORT, RECOVERY AND RESPECTFUL HANDLING OF FALLEN WAR VICTIMS | 202530289349100408 |
| 2024 | Powell Valley Health Care Inc Powell, WY | B | $349,300 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Massachusetts Institute of Technology Cambridge, MA | B | $348,553 | approved, future | COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS | 202530289349100408 |
| 2024 | The Nature Conservancy Arlington, VA | B | $347,804 | approved, future | FUTURE FOREST NYC PHASE III | 202530289349100408 |
| 2024 | Hot Springs County Hospital District Thermopolis, WY | C | $346,794 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Tel Aviv Sourasky Medical Center - Ichilov Hospital Tel Aviv | U | $346,330 | paid | IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $345,527 | paid | EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $344,015 | paid | DIABETESWISE FOR EXERCISE | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $342,955 | approved, future | MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $342,493 | approved, future | APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $341,879 | paid | EXPANSION & EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON INTENSIVE INSULIN THERAPY (IIT) | 202530289349100408 |
| 2024 | Insulin for Life USA Inc Gainesville, FL | B | $341,606 | paid | INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY | 202530289349100408 |
| 2024 | The Imperial College of Science Technology and Medicine London | U | $340,788 | approved, future | IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION | 202530289349100408 |
| 2024 | United Nations Development Programme New York, NY | C | $339,777 | paid | INCREASING ACCESS TO HEALTHCARE FOR PEOPLE LIVING WITH DIABETES AND OTHER NCDS | 202530289349100408 |
| 2024 | Washington University Saint Louis, MO | B | $338,970 | paid | CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $337,310 | paid | MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024) | 202530289349100408 |
| 2024 | Natural Areas Conservancy Inc New York, NY | B | $336,672 | paid | ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3) | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $336,550 | approved, future | FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD OF THE POUCH | 202530289349100408 |
| 2024 | Social Science Research Council Brooklyn, NY | B | $336,025 | approved, future | DATA2GO.NYC REVAMP AND DATA CLINIC | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $334,798 | paid | COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Mayo Clinic Rochester, MN | U | $334,407 | paid | DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES | 202530289349100408 |
| 2024 | The University of Chicago Chicago, IL | U | $333,042 | approved, future | DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $332,512 | approved, future | CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $331,133 | paid | THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA | 202530289349100408 |
| 2024 | Washington University Saint Louis, MI | U | $330,000 | approved, future | RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING | 202530289349100408 |
| 2024 | Washington University Saint Louis, MO | B | $330,000 | paid | RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING | 202530289349100408 |
| 2024 | University of Miami Coral Gables, FL | U | $328,238 | approved, future | THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202530289349100408 |
| 2024 | University of Miami Coral Gables, FL | U | $326,055 | approved, future | THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202530289349100408 |
| 2024 | Ballad Research Institute San Diego, CA | B | $325,801 | paid | CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS | 202530289349100408 |
| 2024 | Association Sante Diabete Grenoble | U | $325,558 | approved, future | STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS | 202530289349100408 |
| 2024 | King's College London London | U | $325,389 | approved, future | RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE. | 202530289349100408 |
| 2024 | Medicines for Humanity Inc Rockland, MA | B | $322,909 | approved, future | MAI MBELEKI II EXPANSION | 202530289349100408 |
| 2024 | Star Valley Medical Center Charitable Foundation Afton, WY | B | $320,890 | paid | STAR VALLEY HEALTH ULTRASOUND PROJECT | 202530289349100408 |
| 2024 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $318,978 | approved, future | CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE | 202530289349100408 |
| 2024 | Minnesota Rural Health Association Henning, MN | C | $318,700 | approved, future | SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA | 202530289349100408 |
| 2024 | Vayu Health Portola Valley, CA | B | $318,000 | approved, future | FEASIBILITY PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH T1D AND T2D. | 202530289349100408 |
| 2024 | Australasian Gastro Intestinal Research Foundation Ltd Fitzroy | U | $315,421 | approved, future | FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY. | 202530289349100408 |
| 2024 | Australasian Gastro Intestinal Research Foundation Ltd Fitzroy | U | $315,421 | approved, future | FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY. | 202530289349100408 |
| 2024 | Ballad Research Institute San Diego, CA | B | $315,380 | approved, future | CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN | 202530289349100408 |
| 2024 | Emory University Atlanta, GA | U | $313,686 | paid | CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $313,168 | approved, future | B CELL SIGNATURES IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Pulitzer Center On Crisis Reporting Washington, DC | C | $310,123 | paid | BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION | 202530289349100408 |
| 2024 | Nevada Department of Health and Human Services Lincoln, NE | U | $309,887 | paid | NEBRASKA FIRST RESPONDER AED PROJECT | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $308,267 | paid | PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13 | 202530289349100408 |
| 2024 | King's College London London | U | $307,779 | approved, future | HYPO - RESOLVE - EVALUATION OF BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $307,674 | paid | STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Amc Medical Research Bv Amsterdam | U | $306,900 | approved, future | IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $305,349 | paid | NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE | 202530289349100408 |
| 2024 | City Parks Foundation New York, NY | B | $305,108 | paid | NYC GREEN FUND | 202530289349100408 |
| 2024 | Universite Catholique de Louvain Louvainlaneuve | U | $304,033 | approved, future | SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM | 202530289349100408 |
| 2024 | Sapir Academic College Regional Council Shaar Ha | U | $303,000 | approved, future | PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING | 202530289349100408 |
| 2024 | Emory University Atlanta, GA | U | $302,430 | approved, future | CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION | 202530289349100408 |
| 2024 | Fjc New York, NY | B | $300,000 | approved, future | NYC FUND TO END YOUTH & FAMILY HOMELESSNESS, A PROJECT OF FJC. | 202530289349100408 |
| 2024 | Yad Sarah Jerusalem | D | $300,000 | paid | EMERGENCY EQUIPMENT PURCHASES | 202530289349100408 |
| 2024 | The Weizmann Institute of Science Rehovot | D | $300,000 | approved, future | QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $300,000 | paid | MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL | 202530289349100408 |
| 2024 | Supportive Housing Network of New York Inc New York City, NY | C | $300,000 | paid | TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS | 202530289349100408 |
| 2024 | The City of Hope Duarte, CA | U | $300,000 | approved, future | THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE | 202530289349100408 |
| 2024 | Fjc New York, NY | B | $300,000 | paid | NYC FUND TO END YOUTH & FAMILY HOMELESSNESS, A PROJECT OF FJC. | 202530289349100408 |
| 2024 | Supportive Housing Network of New York Inc New York City, NY | C | $300,000 | approved, future | TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $300,000 | approved, future | MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL | 202530289349100408 |
| 2024 | Middle East Media and Research Institute Inc Washington, DC | B | $300,000 | paid | THE INTERCONNECTED IRAN-RUSSIA-CHINA AXIS | 202530289349100408 |
| 2024 | Yale University New Haven, CT | U | $298,606 | paid | EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE | 202530289349100408 |
| 2024 | St Vincent's Institute of Medical Research Melbourne | U | $298,224 | approved, future | WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D? | 202530289349100408 |
| 2024 | Benaroya Research Institute at Virginia Mason Seattle, WA | B | $297,957 | paid | TRUCULTURE SAMPLE ANALYSIS FOR TN22 HCQ | 202530289349100408 |
| 2024 | Crohn's and Colitis Canada Toronto | U | $297,612 | approved, future | IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE | 202530289349100408 |
| 2024 | International Bowel Ultrasound Group Ev Munster | U | $296,500 | approved, future | DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED) | 202530289349100408 |
| 2024 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $293,370 | paid | THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $292,821 | paid | CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE | 202530289349100408 |
| 2024 | Palo Alto Veterans Institute for Research Palo Alto, CA | B | $292,821 | paid | CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE | 202530289349100408 |
| 2024 | South Lincoln Hospital District Kemmerer, WY | D | $291,933 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Kaiser Foundation Health Plan of Georgia Inc Atlanta, GA | C | $291,280 | paid | EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL | 202530289349100408 |
| 2024 | University of Utah Salt Lake City, UT | B | $290,806 | approved, future | INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN+ DENDRITIC CELLS | 202530289349100408 |
| 2024 | University of Utah Salt Lake City, UT | B | $290,806 | paid | INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN+ DENDRITIC CELLS | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $290,049 | paid | COMBINATORIAL SINGLE CELL STRATEGIES FOR A CROHN'S DISEASE GUT CELL ATLAS | 202530289349100408 |
| 2024 | Nebraska Methodist Hospital Foundation Omaha, NE | C | $290,000 | paid | NICU EQUIPMENT | 202530289349100408 |
| 2024 | Benaroya Research Institute at Virginia Mason Seattle, WA | B | $288,200 | approved, future | LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D | 202530289349100408 |
| 2024 | St Peter's Health Foundation Helena, MT | B | $288,057 | paid | TRANSCRANIAL MAGNETIC STIMULATION (TMS) SUITE | 202530289349100408 |
| 2024 | Joslin Diabetes Center Inc Boston, MA | B | $287,280 | approved, future | AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES | 202530289349100408 |
| 2024 | University of Miami Coral Gables, FL | U | $286,197 | approved, future | DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES | 202530289349100408 |
| 2024 | American Heart Association Inc Dallas, TX | B | $286,146 | paid | HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE | 202530289349100408 |
| 2024 | Trustees of the University of Pennsylvania Philadelphia, PA | B | $285,079 | paid | THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Crohn's and Colitis Canada Toronto | U | $284,646 | paid | IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE | 202530289349100408 |
| 2024 | Action4diabetes Taunton | U | $284,390 | approved, future | PHILIPPINES T1D TASK FORCE | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $283,542 | paid | EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY | 202530289349100408 |
| 2024 | Emory University Atlanta, GA | U | $283,099 | approved, future | CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION | 202530289349100408 |
| 2024 | University of Pittsburgh Pittsburgh, PA | B | $280,115 | paid | SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | King's College London London | U | $278,644 | approved, future | CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS | 202530289349100408 |
| 2024 | American Diabetes Association Inc Arlington, VA | B | $278,350 | paid | MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024) | 202530289349100408 |
| 2024 | Medical University of South Carolina Charleston, SC | C | $275,000 | approved, future | ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The University of Texas Southwestern Medical Center Dallas, TX | D | $275,000 | paid | IMMUNE CHECKPOINT ENGINEERED BETA CELL AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF TYPE I DIABETES | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $275,000 | approved, future | DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEWAPPROACHES TO PREVENT HYPOGLYCEMIA | 202530289349100408 |
| 2024 | Vanderbilt University Nashville, TN | C | $275,000 | approved, future | NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING | 202530289349100408 |
| 2024 | Vanderbilt University Nashville, TN | C | $275,000 | paid | NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING | 202530289349100408 |
| 2024 | University of Oulu Oulu | U | $274,391 | approved, future | MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $273,882 | approved, future | VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING | 202530289349100408 |
| 2024 | Solidaridad Network Foundation Limited Lusaka | U | $273,384 | approved, future | HOOVES FOR SUSTAINABILITY (H4S) | 202530289349100408 |
| 2024 | St John's Hospital Foundation Jackson, MS | U | $273,054 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $272,555 | paid | THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D | 202530289349100408 |
| 2024 | University at Buffalo Pediatric Associates P C Buffalo, NY | D | $272,233 | paid | FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $269,368 | approved, future | PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO) | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $269,368 | approved, future | PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO) | 202530289349100408 |
| 2024 | Tel Aviv Sourasky Medical Center - Ichilov Hospital Tel Aviv | U | $268,340 | approved, future | IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS | 202530289349100408 |
| 2024 | Alimentiv Inc London | U | $267,835 | paid | DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES | 202530289349100408 |
| 2024 | Critical Path Institute Tucson, AZ | B | $266,741 | approved, future | T1D CONSORTIUM 2.0 | 202530289349100408 |
| 2024 | Critical Path Institute Tucson, AZ | B | $266,741 | paid | T1D CONSORTIUM 2.0 | 202530289349100408 |
| 2024 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $266,667 | approved, future | NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS | 202530289349100408 |
| 2024 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $266,667 | paid | NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS | 202530289349100408 |
| 2024 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $266,666 | approved, future | NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $266,200 | paid | FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02 | 202530289349100408 |
| 2024 | Consorci Institut D'investigaciones Biomedicas August Pi I Sunyer Barcelona | U | $261,570 | paid | EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING | 202530289349100408 |
| 2024 | Social Science Research Council Brooklyn, NY | B | $261,421 | paid | DATA2GO.NYC REVAMP AND DATA CLINIC | 202530289349100408 |
| 2024 | Bighorn Valley Health Center Inc Hardin, MT | B | $260,119 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $260,103 | paid | FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CROHN'S-LIKE DISEASE OF THE POUCH | 202530289349100408 |
| 2024 | Alimentiv Inc London | U | $259,951 | approved, future | DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES | 202530289349100408 |
| 2024 | St Vincent's Institute of Medical Research Melbourne | U | $255,857 | approved, future | WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D? | 202530289349100408 |
| 2024 | Kaiser Foundation Health Plan of Georgia Inc Atlanta, GA | C | $255,687 | approved, future | EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL | 202530289349100408 |
| 2024 | The Tel Aviv Jaffa Academic College Tel Aviv Yaffo | U | $253,818 | paid | SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX (HAREDI) MEN PURSUING B.S. DEGREES IN NURSING | 202530289349100408 |
| 2024 | Villages of Hope Africa Society Mississauga | D | $253,122 | paid | INFRASTRUCTURE IMPROVEMENTS AND EXPANSION | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $251,607 | paid | B CELL SIGNATURES IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Genome Research Limited for the Wellcome Sanger Institute Cambridge | U | $251,522 | paid | SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Massachusetts Institute of Technology Cambridge, MA | B | $251,447 | paid | COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS | 202530289349100408 |
| 2024 | The Hospital for Sick Children Toronto | U | $250,415 | approved, future | IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION | 202530289349100408 |
| 2024 | The Milken Institute Santa Monica, CA | B | $250,000 | approved, future | FASTERCURES LEADERSLINK PROGRAM EXPANSION | 202530289349100408 |
| 2024 | Mayo Clinic Rochester, MN | U | $250,000 | paid | MILITARY SCIENCES MEDICAL TRAINING 2022-2024 | 202530289349100408 |
| 2024 | The Milken Institute Santa Monica, CA | B | $250,000 | paid | FASTERCURES LEADERSLINK PROGRAM EXPANSION | 202530289349100408 |
| 2024 | Israel Emergency Alliance Los Angeles, CA | C | $250,000 | paid | SUPPORT OF LEGAL EFFORTS TO COMBAT ANTISEMITISM, AND SOCIAL MEDIA EXPANSION | 202530289349100408 |
| 2024 | Jdrf International New York, NY | U | $250,000 | approved, future | JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES | 202530289349100408 |
| 2024 | Jdrf International New York, NY | U | $250,000 | approved, future | JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES | 202530289349100408 |
| 2024 | The Chinese University of Hong Kong Shatin | U | $249,337 | paid | IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY | 202530289349100408 |
| 2024 | The Hospital for Sick Children Toronto | U | $248,621 | approved, future | IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION | 202530289349100408 |
| 2024 | The Governors of the University of Calgary Calgary | D | $247,654 | paid | QUANTITATIVE PROTEOMIC PROFILING OF FIBROSTENOTIC CROHNS DISEASE PATIENTS | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $246,662 | paid | AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT | 202530289349100408 |
| 2024 | Chancellor Masters & Scholars of the University of Oxford Oxford | D | $244,860 | approved, future | THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD | 202530289349100408 |
| 2024 | Chancellor Masters & Scholars of the University of Oxford Oxford | D | $244,860 | paid | THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD | 202530289349100408 |
| 2024 | Ballad Research Institute San Diego, CA | B | $243,390 | approved, future | CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $243,216 | paid | THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION | 202530289349100408 |
| 2024 | University of Pittsburgh Pittsburgh, PA | B | $243,196 | paid | SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Renown Health Foundation Reno, NV | B | $243,019 | approved, future | RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA | 202530289349100408 |
| 2024 | University of Miami Coral Gables, FL | U | $242,826 | approved, future | DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $241,173 | paid | PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO) | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $241,173 | paid | PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO) | 202530289349100408 |
| 2024 | Academisch Ziekenhuis Leiden Leiden | U | $238,910 | approved, future | SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II) | 202530289349100408 |
| 2024 | University of Pittsburgh Pittsburgh, PA | B | $237,102 | approved, future | SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE | 202530289349100408 |
| 2024 | The Cleveland Clinic Foundation Cleveland, OH | C | $236,313 | approved, future | THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $235,821 | approved, future | B CELL SIGNATURES IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The City of Hope Duarte, CA | U | $235,681 | approved, future | GENETIC PROTECTION BY HLA-DQ6 IN T1D | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $232,525 | approved, future | ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Academisch Ziekenhuis Leiden Leiden | U | $230,038 | paid | SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II) | 202530289349100408 |
| 2024 | Chi Health Foundation Omaha, NE | U | $229,460 | approved, future | ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY | 202530289349100408 |
| 2024 | Chi Health Foundation Omaha, NE | U | $229,460 | approved, future | ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY | 202530289349100408 |
| 2024 | Uppsala Universitet Uppsala | U | $229,347 | paid | ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION | 202530289349100408 |
| 2024 | Children's Hospital of Philadelphia Philadelphia, PA | C | $228,375 | approved, future | LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $228,040 | approved, future | FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT | 202530289349100408 |
| 2024 | Amc Medical Research Bv Amsterdam | U | $225,500 | approved, future | IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE | 202530289349100408 |
| 2024 | Nevada Department of Health and Human Services Carson City, NV | U | $223,920 | paid | NEVADA FIRST RESPONDER AED PROJECT | 202530289349100408 |
| 2024 | Action4diabetes Taunton | U | $222,500 | approved, future | PHILIPPINES T1D TASK FORCE | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $221,931 | paid | SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA | 202530289349100408 |
| 2024 | Chancellor Masters & Scholars of the University of Oxford Oxford | D | $221,420 | paid | INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $221,407 | approved, future | EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $220,565 | approved, future | THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D | 202530289349100408 |
| 2024 | The Max Stern Academic College of Emek Yezreel Ltd (cc) Yezreel Valley | U | $220,000 | paid | OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN-ISRAELIS PURSUING NURSING DEGREES | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $220,000 | approved, future | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES | 202530289349100408 |
| 2024 | Icahn School of Medicine at Mount Sinai New York City, NY | B | $220,000 | paid | VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $219,514 | approved, future | A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY | 202530289349100408 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | U | $217,916 | approved, future | IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS | 202530289349100408 |
| 2024 | Minnesota State Colleges and Universities St Paul, MN | U | $217,428 | approved, future | EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA | 202530289349100408 |
| 2024 | The University of Adelaide Adelaide | U | $217,136 | paid | PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN | 202530289349100408 |
| 2024 | Universite Libre de Bruxelles Brussels | U | $213,602 | approved, future | GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING | 202530289349100408 |
| 2024 | Universite Libre de Bruxelles Brussels | U | $213,582 | paid | GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $212,881 | paid | HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $211,815 | approved, future | A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY | 202530289349100408 |
| 2024 | Technische Universitat Dresden Dresden | U | $210,829 | paid | GENOMIC INFLUENCE OF MATERNAL TYPE 1 DIABETES - UNDERSTANDING PROTECTION AGAINST TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Australasian Gastro Intestinal Research Foundation Ltd Fitzroy | U | $209,377 | approved, future | FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY. | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $209,222 | approved, future | HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE | 202530289349100408 |
| 2024 | King's College London London | U | $208,787 | approved, future | CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS | 202530289349100408 |
| 2024 | The Rector and Visitors of the University of Virginia Charlottesville, VA | C | $206,088 | paid | TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $205,983 | approved, future | EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY | 202530289349100408 |
| 2024 | Minnesota State Colleges and Universities St Paul, MN | U | $205,285 | approved, future | EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA | 202530289349100408 |
| 2024 | University of Iowa Iowa City, IA | U | $204,566 | approved, future | SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION | 202530289349100408 |
| 2024 | Duke University Durham, NC | B | $203,497 | paid | UTILIZING AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS TO PREVENT INSULIN-INDUCED HYPOGLYCEMIA IN T1D | 202530289349100408 |
| 2024 | University of Melbourne Victoria | D | $203,056 | paid | USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $202,791 | paid | A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY | 202530289349100408 |
| 2024 | Chancellor Masters & Scholars of the University of Oxford Oxford | D | $202,677 | approved, future | ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA | 202530289349100408 |
| 2024 | Weill Medical College of Cornell University New York, NY | U | $202,620 | approved, future | TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Texas System for the University of Texas at Austin Austin, TX | U | $200,927 | approved, future | INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN | 202530289349100408 |
| 2024 | University of Texas System for the University of Texas at Austin Austin, TX | U | $200,927 | approved, future | INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $200,584 | approved, future | EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D | 202530289349100408 |
| 2024 | Cedars-Sinai Medical Center Los Angeles, CA | B | $200,041 | paid | A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY | 202530289349100408 |
| 2024 | Youth Development Organization Inc Lawrence, MA | B | $200,000 | approved, future | CAPACITY BUILDING PROJECT SUPPORT 2024-2026 | 202530289349100408 |
| 2024 | Supportive Housing Network of New York Inc New York City, NY | C | $200,000 | approved, future | TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS | 202530289349100408 |
| 2024 | Jdrf International New York, NY | U | $200,000 | approved, future | CO-FUNDED DEVELOPMENT OF A 3--HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $200,000 | paid | ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | For Inspiration and Recognition of Science and Technology Manchester, NH | C | $200,000 | paid | FIRST SENIOR MENTOR PROGRAM | 202530289349100408 |
| 2024 | For Inspiration and Recognition of Science and Technology (first) Manchester, NH | B | $200,000 | approved, future | FIRST SENIOR MENTOR PROGRAM | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $200,000 | approved, future | SUPPORT FOR T1D TRANSITION PROGRAMS | 202530289349100408 |
| 2024 | Crohn's & Colitis Foundation Inc New York, NY | B | $200,000 | paid | SPONSORSHIP FOR THE 2024 CROHNS & COLITIS CONGRESS PRESENTED BY THE CROHNS & COLITIS FOUNDATION AND THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION | 202530289349100408 |
| 2024 | Shatterproof a Nonprofit Corp Norwalk, CT | U | $200,000 | approved, future | GENERAL OPERATING SUPPORT | 202530289349100408 |
| 2024 | Youth Development Organization Inc Lawrence, MA | B | $200,000 | approved, future | CAPACITY BUILDING PROJECT SUPPORT 2024-2026 | 202530289349100408 |
| 2024 | Youth Development Organization Inc Lawrence, MA | B | $200,000 | paid | CAPACITY BUILDING PROJECT SUPPORT 2022 | 202530289349100408 |
| 2024 | For Inspiration and Recognition of Science and Technology (first) Manchester, NH | B | $200,000 | approved, future | FIRST SENIOR MENTOR PROGRAM | 202530289349100408 |
| 2024 | Fuente Latina Inc Miami, FL | C | $200,000 | paid | MEDIA FELLOWSHIPS TO ISRAEL | 202530289349100408 |
| 2024 | University of Iowa Iowa City, IA | U | $199,968 | approved, future | SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION | 202530289349100408 |
| 2024 | South Big Horn County Hospital District Basin, WY | U | $199,845 | paid | THREE RIVERS HEALTH ULTRASOUND PROJECT | 202530289349100408 |
| 2024 | Katholieke Universiteit Te Leuven Leuven | U | $199,460 | approved, future | EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY | 202530289349100408 |
| 2024 | University of Texas System for the University of Texas at Austin Austin, TX | U | $198,646 | approved, future | INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN | 202530289349100408 |
| 2024 | University of Texas System for the University of Texas at Austin Austin, TX | U | $198,646 | paid | INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN | 202530289349100408 |
| 2024 | Amc Medical Research Bv Amsterdam | U | $197,373 | paid | DEVELOPMENT AND VALIDATION OF AN EPIGENETIC BIOMARKER THAT PREDICTS TREATMENT SUCCESS AND ALLOWS PERSONALIZED MANAGEMENT IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Board of Regents Nevada System of Higher Education Reno, NV | B | $197,208 | approved, future | ULTRASOUND TRAINING INITIATIVE IN NEVADA | 202530289349100408 |
| 2024 | Board of Regents Nevada System of Higher Education Reno, NV | B | $197,208 | paid | ULTRASOUND TRAINING INITIATIVE IN NEVADA | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $196,582 | paid | MRI OF THE PANCREAS IN T1D | 202530289349100408 |
| 2024 | University of Texas System for the University of Texas at Austin Austin, TX | U | $196,411 | paid | INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $196,089 | approved, future | EUROPEAN PRE-T1D REGISTRY | 202530289349100408 |
| 2024 | King's College London London | U | $195,494 | paid | IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $194,126 | approved, future | VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING | 202530289349100408 |
| 2024 | Board of Trustees of the Leland Stanford Junior University Stanford, CA | B | $193,790 | approved, future | DIABDOCS NATIONAL K12: SUPPLEMENT | 202530289349100408 |
| 2024 | The Governors of the University of Calgary Calgary | D | $191,883 | paid | THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $191,816 | approved, future | LEVERAGING NEW ULTRA-RAPID INSULINS WITH AID FOR EXERCISE MANAGEMENT WITH T1D | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $190,677 | paid | DEVELOPING OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES | 202530289349100408 |
| 2024 | Reachanother Foundation Bend, OR | U | $190,186 | approved, future | EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA | 202530289349100408 |
| 2024 | University of Exeter Exeter | U | $189,671 | approved, future | UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The Sheba Fund for Health Services and Research (ra) Ramat Gan | U | $188,118 | approved, future | ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE & OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD) | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $188,007 | approved, future | EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY | 202530289349100408 |
| 2024 | Genome Research Limited for the Wellcome Sanger Institute Cambridge | U | $187,672 | approved, future | SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE | 202530289349100408 |
| 2024 | Regents of the University of Michigan Ann Arbor, MI | C | $187,370 | paid | EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE | 202530289349100408 |
| 2024 | The Sonia Nabeta Foundation Inc Long Island City, NY | C | $184,889 | paid | PROJECT BODA-BODA | 202530289349100408 |
| 2024 | New Destiny Housing Corporation New York, NY | B | $183,350 | approved, future | PILOTING AFTERCARE INTERVENTIONTO IMPROVE HOUSING AND HEALTH STABILITYFOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS | 202530289349100408 |
| 2024 | Arad Municipality Arad | U | $183,236 | paid | ARAD OCCUPATIONAL REHABILITATION CENTER | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $182,168 | approved, future | ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The University of Adelaide Adelaide | U | $181,471 | paid | ENDIA SCIENCE CONTINUATION | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $179,943 | paid | EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $179,714 | paid | UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES. | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $176,459 | paid | MRI OF THE PANCREAS IN T1D | 202530289349100408 |
| 2024 | University of Glasgow Court Glasgow | U | $176,239 | approved, future | COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY | 202530289349100408 |
| 2024 | Shaare Zedek Medical Center Jerusalem | D | $174,719 | paid | PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK: THE PIONIR TRIAL (PREVENTING IBD ONSET IN INDIVIDUALS AT RISK) | 202530289349100408 |
| 2024 | Albert Einstein College of Medicine Bronx, NY | B | $173,613 | approved, future | ENHANCING THE COMMUNITY HEALTH WORKER MODEL TO PROMOTE DIABETES TECHNOLOGY USE IN ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY | 202530289349100408 |
| 2024 | St Rose Dominican Health Foundation Henderson, NV | U | $172,840 | approved, future | DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Billings Clinic Foundation Billings, MT | B | $172,365 | paid | BILLINGS CLINIC CODY ULTRASOUND PROJECT | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $172,204 | paid | MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC) | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $170,401 | paid | DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEWAPPROACHES TO PREVENT HYPOGLYCEMIA | 202530289349100408 |
| 2024 | Shatterproof a Nonprofit Corp Norwalk, CT | U | $170,000 | approved, future | GENERAL OPERATING SUPPORT | 202530289349100408 |
| 2024 | Albert Einstein College of Medicine Bronx, NY | B | $168,556 | paid | PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY | 202530289349100408 |
| 2024 | Regents of the University of Minnesota Minneapolis, MN | U | $166,880 | approved, future | THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D | 202530289349100408 |
| 2024 | Arad Municipality Arad | U | $166,407 | paid | EMERGENCY FUNDING FOR SAFETY AND SECURITY EQUIPMENT | 202530289349100408 |
| 2024 | The City of Hope Duarte, CA | U | $165,000 | paid | CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY | 202530289349100408 |
| 2024 | Institut Integrated Biobank of Luxembourg Dudelange | U | $164,873 | approved, future | BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $163,405 | approved, future | ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES | 202530289349100408 |
| 2024 | The University of Adelaide Adelaide | U | $163,010 | paid | ENDIA EXPANDED SUPPORT | 202530289349100408 |
| 2024 | Helmholtz Zentrum Munchen (gmbh) Neuherberg | U | $162,877 | approved, future | GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN | 202530289349100408 |
| 2024 | The Jewish Agency for Israel Jerusalem | D | $161,477 | paid | THE JEWISH AGENCY SECURITY FUND (THE FUND) | 202530289349100408 |
| 2024 | Jaeb Center for Health Research Foundation Inc Tampa, FL | C | $159,838 | approved, future | EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY | 202530289349100408 |
| 2024 | The University of Edinburgh Edinburgh | U | $159,623 | paid | UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES. | 202530289349100408 |
| 2024 | The Regents of the University of Colorado Denver Aurora, CO | D | $157,700 | paid | DIABETIC KETOACIDOSIS TRENDS AND RESOURCE UTILIZATION AT DIAGNOSIS OF TYPE 1 DIABETES IN THE UNITED STATES | 202530289349100408 |
| 2024 | The University of Queensland Brisbane | D | $156,746 | paid | GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY | 202530289349100408 |
| 2024 | Action4diabetes Taunton | U | $156,500 | paid | PHILIPPINES T1D TASK FORCE | 202530289349100408 |
| 2024 | North Big Horn Hospital Lovell, WY | B | $153,800 | paid | NORTH BIG HORN HOSPITAL WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | Centre Hospitalier Regional de Nancy Nancy | U | $153,102 | approved, future | PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT | 202530289349100408 |
| 2024 | University of Birmingham Birmingham | U | $152,801 | approved, future | DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY | 202530289349100408 |
| 2024 | Universite Catholique de Louvain Louvainlaneuve | U | $152,546 | approved, future | SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM | 202530289349100408 |
| 2024 | American Friends of Magen David Adom New York, NY | B | $152,000 | paid | EMERGENCY SUPPORT FOR MAGEN DAVID ADOM | 202530289349100408 |
| 2024 | Technische Universitaet Muenchen Munchen | U | $151,947 | approved, future | COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Mayo Clinic Rochester, MN | U | $151,705 | approved, future | DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $150,000 | approved, future | SUPPORT FOR T1D TRANSITION PROGRAMS | 202530289349100408 |
| 2024 | Adi Negev-Nahalat Eran Ra Ofakim | U | $150,000 | paid | REHABILITATION WARD EQUIPMENT PROJECT | 202530289349100408 |
| 2024 | National Academy of Sciences Washington, DC | C | $150,000 | approved, future | STRENGTHENING MINORITY SERVING INSTITUTIONS | 202530289349100408 |
| 2024 | Institute for Monitoring Peace and Cultural Tolerance in School Education Ramat Gan | U | $150,000 | approved, future | TRANSFORMING EDUCATION FOR PEACE: A NATIONWIDE AWARENESS CAMPAIGN ON INCITEMENT IN PALESTINIAN/UNRWA TEXTBOOKS. | 202530289349100408 |
| 2024 | The Health & Housing Consortium Inc Bronx, NY | C | $150,000 | paid | NYC HEALTH & HOUSING CONSORTIUM: STRATEGIZING FOR SUSTAINABILITY | 202530289349100408 |
| 2024 | Alyn Hospital - Rehabilitation Center for Children and Youth Jerusalem | U | $150,000 | paid | CREATION OF EMERGENCY MEDICAL AIR-RAID SHELTER | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $149,796 | approved, future | GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES | 202530289349100408 |
| 2024 | University of North Carolina at Chapel Hill Chapel Hill, NC | B | $149,796 | paid | GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES | 202530289349100408 |
| 2024 | Center for Health Care Strategies Inc Hamilton, NJ | B | $149,672 | approved, future | IDENTIFYING OPPORTUNITIES TO SUPPORT T1D AUTOANTIBODY SCREENING IN MEDICAID PROGRAMS AND HEALTH CARE SYSTEMS THAT SERVE MEDICAID BENEFICIARIES | 202530289349100408 |
| 2024 | Beyond Type 1 San Mateo, CA | D | $149,166 | paid | DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3 | 202530289349100408 |
| 2024 | Niobrara County Hospital District Lusk, WY | D | $147,400 | paid | WYOMING ULTRASOUND REVITALIZATION PROJECT | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $146,689 | approved, future | ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THEHEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOMENEW YORKERS | 202530289349100408 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | B | $146,368 | paid | PRE-SYMPTOMATIC AUTOANTIBODY AND VIRAL PROFILE OF US MILITARY PERSONNEL WITH ADULT-ONSET TYPE 1 DIABETES | 202530289349100408 |
| 2024 | Vanderbilt University Medical Center Nashville, TN | C | $145,749 | paid | EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $145,605 | approved, future | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT | 202530289349100408 |
| 2024 | Jdrf International New York, NY | U | $145,404 | approved, future | HELMSLEY AND JDRF CO-FUNDED WORKSHOPS | 202530289349100408 |
| 2024 | Herlev Og Gentofte Hospital Herlev | U | $145,339 | paid | TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D | 202530289349100408 |
| 2024 | Genome Research Limited for the Wellcome Sanger Institute Cambridge | U | $143,892 | approved, future | SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE | 202530289349100408 |
| 2024 | University of Notre Dame du Lac Notre Dame, IN | U | $143,127 | paid | DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM | 202530289349100408 |
| 2024 | The Trustees of Columbia University in the City of New York New York, NY | U | $143,021 | paid | ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THEHEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOMENEW YORKERS | 202530289349100408 |
| 2024 | Regents of the University of Michigan Ann Arbor, MI | C | $142,264 | paid | A SYSTEM BIOLOGY APPROACH TO UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE | 202530289349100408 |
| 2024 | Cozad Hospital District No 2 Cozad, NE | D | $141,545 | paid | TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM | 202530289349100408 |
| 2024 | Herlev Og Gentofte Hospital Herlev | U | $140,000 | approved, future | TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D | 202530289349100408 |
| 2024 | Clalit Health Services Tel Aviv | U | $138,626 | paid | ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT | 202530289349100408 |
| 2024 | Medical University of South Carolina Charleston, SC | C | $137,500 | approved, future | ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES | 202530289349100408 |
| 2024 | University of Oulu Oulu | U | $137,453 | paid | MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING | 202530289349100408 |
| 2024 | The Governors of the University of Calgary Calgary | D | $137,417 | approved, future | INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD | 202530289349100408 |
| 2024 | Board of Regents Nevada System of Higher Education Reno, NV | B | $137,345 | approved, future | CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM | 202530289349100408 |
| 2024 | The Governors of the University of Calgary Calgary | D | $137,153 | paid | INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD | 202530289349100408 |
| 2024 | The Association for the Resident and Community in Ramat Hanegev Ramat Hanegev | U | $136,393 | paid | RAMAT HANEGEV SENIOR CITIZEN CENTER | 202530289349100408 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.